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CHAPTER 1 
INTRODUCTION 

The Hepatitis B Virus 
The hepatitis B virus (HBV) is a double-stranded DNA virus belonging to the group of 
hepadna viridae (1). The replication of HBV is believed to occur preferentially in the 
hepatocyte. Analysis of the nucleotide sequence of the virus revealed 4 open reading 
frames, regions of the genome which may code for viral antigens (1). Although the HBV 
genome contains only 3200 nucleotides its compacmess and circnlar composition, 
employing overlapping genes for production of several viral proteins, make the virus 
highly efficient for replication. The replication cycle of HBV is illustrated in figure 1. 
After entry in the hepatocyte the virus is uncoated and the genomic DNA is converted to a 
supercoiled form of covalently closed fully double stranded DNA which is transcribed to 
pregenontic and messenger RNA. Viral messenger RNA is transported to the cytoplasm 
HBV RNA preger'\Ome, -o H8sAg. 0 HBcAg. 6 HSVONA polymerase, e 
HBcAg-MHC class 1 ant1gen-HBs Ag. + 
Figure 1. HBV replication cycle in hepaJocytes. DNA-P: DNA polymerase; HBcAg: 
hepatitis B core antigen; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; 
MHC: ITI£ljor histocompatibility complex; RNA-p: RNA polymerase. !from L. Berk et al. 
Current Opinion in Infectious Diseases 1989;2:419-23; with permission). 
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where it codes for production of viral proteins. Pregenomic RNA is reverse transcrihed 
into a minus strand of DNA which is utilized as a template for completion of the plus 
strand of the newly synthesized viral DNA. The HBV -DNA-polymerase enzyme which 
exerts both a DNA polymerase and a reverse transcriptase activity plays a crucial role in 
the replication cycle of the virus. 
Chronic Hepatitis B 
Inoculation with the virus causes hepatocellular necrosis and inflammation which ranges in 
severity from an asymtomatic infection that resolves completely to severe, symptomatic 
infection with progressive or even fatal illness (2). It is still not clear why certain patients 
progress to a chronic hepatitis B infection while the majority clears HBV after an acute 
infection. One of the possibilities is that chronic HBV carriage results in part from a 
deficiency in IFN production. Several studies have showed a lower endogeneous IFN 
response in individuals with chronic hepatitis B (3). This low IFN production is likely to 
impair the display of HLA class I proteins and thereby impede the clearance of 
hepatocytes harbouring replicating virus (4). 
In the patients who develop a chronic hepatitis there is a substantial risk of disease 
progression to cirrhosis, portal hypertension and hepatocellular carcinoma (5,6; figure 2). 
It is unlikely that HBV causes its damaging effect on liver cells by direct cytopathogenic 
changes because large quantities of HBsAg and HBcAg are found in the hepatocytes of 
many asymptomatic and appearantly healthy HBV carriers. Both for the pathogenesis of 
the liver damage and for succesful eradication of the disease the interaction between 
various structural components of the virus and the immune system appear to be essential. 
In untreated chronic hepatitis B patients HBV probably replicates less vigorously as time 
passes, maybe because of an increasing immunological attack on virus-infected 
hepatocytes (7,8). This phenomenon is accompanied by a fall of serum HBV-DNA and 
increased liver damage as signalled by abnormal liver ftmction tests. Cessation of HBV 
replication as indicated by an HBeAg serovonversion and a marked suppression of HBV-
DNA, usually heralds a last and quiescent phase of the disease which may in time be 
followed by a total eradication of the virus (HBsAg seroconversion) (9-11). The process 
of HBeAg seroconversion is often preceded by intense hepatic inflanunation and symptoms 
of fatigue. The aim of antiviral therapy with a-IFN is to assist the host in eliminating 
HBV replication early in the course of the chronic infection. 
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Figure 2. Course of hepatitis B infection. 
Alpha-Interferon Treatment of Chronic Hepatitis B 
carcinoma 
Intervention treatment of chronic hepatitis B is targeted at patients with active viral 
replication, preferably at a stage before signs and symptoms of cirrhosis or significant 
disease activity have occurred. Although the genetic heterogeneity of HBV, recently 
disclosed by molecular biology (12), has necessitated a reconsideration of the classical 
serologic distinctions between active virus replication and viral latency, the presence of 
HBeAg and HBV-DNA is still considered to be the main indication for antiviral therapy. 
a-IFN probably interferes directly with HBV production by activation of intracellular 
enzymes like 2'-5' oligoadenylate synthetase or protein kinase, leading to an activation of 
ribonucleases that destroy viral messenger RNA. As hrnnune modifying substance a-IFN 
augments the natural killer cell activity and causes enhanced expression of HLA class I 
proteins on the hepatocyte surface thereby facilitating recognition and lysis of virus-
infected cells by the cellular hrnnune system (13). In addition, a-IFN may boost the 
production of the HBV transcripts that code for HBcAg thereby promoting an increased 
hepatocyte membrane expression of this antigen which is one of the key viral proteins 
recognised by the cytotoxic T cells (14). 
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Although a-IFN is the first agent which has repeatedly shown efficacy for chronic 
hepatitis B in large randomized controlled trials, more than half of the patients do not 
respond and are left with continuing disease activity (15,16). Because several individual 
variables (e.g. high level of inflammatory activity, low level of virus replication and a 
short duration of infection) are associated with a higher response rate (17,18) and because 
the adverse effects of a-IFN are often a cause dose reduction, timing and dosage of a-IFN 
are important in deterntining the potency of this therapy. The scope of this thesis is 
comprised to the question how we could safely improve the indication for and antiviral 
effect of a-IFN therapy in chronic hepatitis type B. 
The objectives of the study are: 
1. To assess the prognostic role of HBeAg seroconversion in patients with HBV-related 
cirrhosis of the liver (chapter 2). 
2. To evaluate the efficacy of modifications (prolonged intermittent therapy, 
combination therapy with zidovudine and a-IFN retreatrnent) of a-IFN treatment in 
chronic hepatitis B (chapter 3, 4 and 5). 
3. To evaluate the usefulness of quantitated HBV-DNA and HBsAg assessments for 
monitoring of chronic hepatitis B patients undergoing a-IFN therapy (chapter 6 and 
7). 
4. To review the frequency and clinical aspects of serious side effects (fatal hepatic 
decompensation, seizures and suicidal behaviour) associated with a-IFN therapy for 
chronic viral hepatitis (chapter 8, 9 and 10). 
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CHAPTER2 
SURVIVAL AND PROGNOSTIC INDICATORS IN HBsAg-POSITIVE CIRRHOSIS 
OF THE LIVER. THE ROLE OF HBeAg SEROCONVERSION. 
F.E. de Jongh1, H.L.A. Janssen', R.A. de Man1, W.C.J. Hop2, S.W. Schalm1, M. van 
Blankenstein1• 
1. Department of Hepatogastroenterology-lnternal Medicine U. 
2. Department of Epidemiology and Biostatistics. 
University Hospital Dijkzigt, Rotterdam, The Netherlands. 
Gastroenterology 1992;103:1630-1635 
Abstract 
To evaluate indications for new therapies, such as liver transplantation and antiviral therapy, 
we assessed survival of histologically proven HBsAg-positive cirrhosis of the liver in a cohort 
of 98 patients, followed for a mean period of 4.3 years. The overall survival probability was 
92% at 1 year, 79% at 3 years and 71% at 5 years. 
Variables significantly associated with the duration of survival were age, serum aspartate 
aminotransferase levels, the presence of esophageal varices and all 5 components of the 
Child-Pugh index (bilirubin, albumin, coagulation factors, ascites and/or encephalopathy). 
Multivariate analysis showed that ouly age, bilirubin and ascites were independently related 
to survival. 
Survival for patients with decompensated cirrhosis (determined by the presence of ascites 
and/or jaundice and/or encephalopathy and/or a history of variceal bleeding) and compensated 
cirrhosis at 5 years was 14 and 84%, respectively. 
For patients with compensated liver cirrhosis, HBeAg positivity was also a prognostic factor 
with a 5-year survival of 72% for HBeAg-positive cirrhosis and 97% for HBeAg-negative 
cirrhosis; the risk of death was decreased by a factor 2.2 when HBeAg seroconversion 
occurred during follow-up. 
We conclude that liver transplantation should be considered for patients with decompensated 
HBsAg-positive liver cirrhosis and antiviral therapy for patients with HBeAg-positive 
compensated cirrhosis. 
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Introduction 
Chronic hepatitis B is associated with substantial morbidity and mortality dependiog on the 
subgroups as healthy carrier, chronic hepatitis or cirrhosis (1 ,2). Primary hepatocellular 
carcinoma and liver failure probably account for more than 50% of all deaths among HBsAg 
carriers (3,4). Follow-up studies show that mortality is linked predominantly to cirrhosis (1,5-
12). After the development of liver cirrhosis the five-year survival rate varies between 52 and 
80% (9,13-16). Major causes of death for cirrhotic patients are, in order of frequency: 
hepatocellular carcinoma, liver failure and upper gastrointestinal bleeding (17-20). 
Little data on the prognosis of HBsAg-positive cirrhosis for West-European patients are 
available. The present paper reports on mortality of HBsAg-positive liver cirrhosis in a 
predominantly white West-European population. A total of 12 possible determinants of 
survival were analyzed by univariate and multivariate methods. In addition, the prognostic 
role of the hepatitis B e antigen (HBeAg) and the influence of HBeAg-seroconversion on the 
risk of death were detennined. Such analyses may help to defme indications for and timing 
of new treatment modalities such as antiviral therapy and liver transplantation for HBsAg-
positive cirrhosis. 
Patients and Methods 
Patients. 
From January 1970 to June 1990 almost 450 patients with chronic hepatitis B virus (HBV) 
infection visited the Department Hepatogastroenterology of our institution, which serves a 
tertiairy referral function. Eighty-three percent of these patients underwent a liver biopsy. 
Cirrhosis was consecutively diagnosed in 98 patients. The criteria for the diagnosis of HBV-
related cirrhosis were the presence of serum HBsAg and a liver biopsy that showed cirrhosis 
or "probably" cirrhosis (21). Of the non-biopsied pstieuts 4 exhibited signs that could be 
related to advanced liver disease (albumin < 34 gil n=3: ascites n=2; jaundice n=2). 
Because these signs cannot unequivocally be linked to cirrhosis we did not include these 
patients in the study. 
Design of the study. 
We calculated the actuarial survival of the 98 patients with HBsAg-positive cirrhosis who 
visited our department. The following characteristics, present at the beginning of follow-up, 
were evaluated to detennine their prognostic significance for survival: sex, age, subjective 
symptoms, alcohol intake, ascites, encephalopathy, esophageal varices, HBeAg status, 
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serumaspartate aminotransferase (AST), bilirubin, albumin and coagulation factors. In 
addition, the effect of HBeAg-seroconversion during follow-up on mortality was analyzed. 
Follow-up. 
Follow-up started after histopathological confinnation of HBsAg-positive liver cirrhosis or -
when histopathological confirmation had already been obtained elsewhere - at the time of the 
first visit to our department. Clinical and laboratory parameters were followed at regular 
intervals (at least every 6 months). Survival from entry into the study was evaluated up to 1 
September 1990. Three patients who had moved abroad were lost to follow-up. The mean 
follow-up time was 4.3 years (range 0.1 to 18 years). 
Clinical and laboratory assessment. 
HBsAg, HBeAg, antibodies to HBsAg, antibodies to HBeAg and antibodies to the hepatitis 
C and D virus were measured with commercially available enzyme-linked immunosorbent 
assays or solid-phase radioimmunoassays (Abbott Laboratories, North Chicago, Ill., USA). 
The presence of antibodies to hepatitis C was cottflrmed by a recombinant immunoblot assay 
(Ortho). To achieve complete and uniform HBeAg testing, sera obtained before 1980 were 
collected and retested with the presently used radioimmunoassay test system (Abbott, North 
Chicago, Ill., USA). HBeAg-seroconversion was defmed as the absence of serum HBeAg for 
at least six months. AST, bilirubin and albumin were determined with the sequentisl multiple 
autoanalyzer (12-panel SMA; Techniconlnstruments Corp., Tarrytown, N.Y.). Coagulation 
factors were assessed by Normotest' and Trombotest'. 
All biopsy specimens - including those from referring hospitals - were judged by a single 
experienced pathologist according to international standards (21). Ascites was diagnosed by 
physical examination and ultrasonography of the abdomen which was catried out routinely. 
Esophageal varices were present when clearly demonstrated by standardized radiologic 
examination or endoscopy (grade TI, ill or IV) (22). Twelve patients did not undergo 
esophageal examination; esophageal varices were assumed not to be present in these cases. 
Presence of hepatic encephalopathy was confirmed by spectral analysis of the 
electroencephalogram (23). 
Statistical analysis. 
Survival analysis - irrespective of the cause of death - was carried out by the Kaplan-Meier 
method. For univariate analysis the log rank test to compare survival curves was used. 
Variables thst were statistically significant (two-sided, P<0.05) according to the univariate 
analyses were subsequently introduced into the multivariate analysis, as described by Cox 
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(24). The relation between HBeAg seroconversion and subsequent death rates was evaluated 
according to a statistical method that corrected for response-time bias for patients who 
underwent HBeAg seroconversion (25). 
Results 
The initial patient characteristics are presented in table 1. At presentation the median age was 
46 years (range 24-81), the median bilirubin level was 12 f'lllOI/1 (range 8-602; normal< 14 
;<JllOIII) and the median AST level 54 U/1 (range 14-383; normal<30 U/1). Seventy-six 
percent of the patients were West-European caucasians. The risk factors for transmission of 
the HBV were: HBV -positive heterosexual partner in 4%, intravenous drug abuse in 5%, 
blood transfusion in 6%, (para)medical work in 6%, homosexual contacts in 18%, stay in an 
endemic area for HBV in 21% and unknown in 40% of the patients. 
Twenty-six of the 98 patients (27%) died during the follow-up period. Ten patients died of 
hepatocellular carcinoma, I 0 due to liver failure or fatal bleeding of the upper gastrointestinal 
tract and 6 due to non-liver-related causes. Estimated survival for HBsAg-positive liver 
cirrhosis is illustrated in figure l. The overall survival probability was 92% at 1 year, 79% 
at 3 years and 71% at 5 years (95% confidence interval (CI) 86-97%, 71-87% and 62-80% 
respectively). 
Univariate analysis revealed eight variables that were significantly (P<0.05) associated with 
the duration of survival (table 1). The survival was significantly reduced for patients with 
higher age, impaired coagulation status, esophageal varices, ascites, encephalopathy, high 
levels of serum AST and bilirubin, and low levels of serum albumin. AST -levels that 
exceeded twice the upper limit of normal (30 U/1) were associated with a more than twofold 
increase in death risk. 
Thirteen patients were found to be positive for hepatitis delta antibodies (1 died), 2 for 
hepatitis C virus antibodies (0 died) and 2 for HIV antibodies (0 died); 6 patients underwent 
a liver transplantation (3 died). Since the transplantations and part of the testing for these co-
infections were performed during follow-up we separately analyzed these factors; no 
significant effect on survival was found. 
At entry into the study, 54 patients were seropositive for HBeAg. The estimated five-year 
survival rate was 59% for HBeAg-positive patients and 83% for HBeAg-negative patients. 
HBeAg status just failed to be a significant factor that influenced survival for the whole 
patient population (P=0.08). After a mean interval of 16 months, 27 of the HBeAg-positive 
patients underwent HBeAg seroconversion; in 25 of them antibodies to HBeAg subsequently 
developed. The calculated annual HBeAg seroconversion rate was 27%. Almost half of all 
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Table 1. Initial patient characteristics and results of univariate analysis (n = 98). 
n 5-year survival p-value 
Sex Male 89 69 % 0.4 
Female 9 89% 
Age . <36 years 20 100% <0.001 
36-50 years 42 82% 
51-60 years 24 46% 
>60 years 12 41% 
Symptoms Absent 31 84% O.Q7 
Present 67 65 % 
Alcohol ;S;40 g/day 86 69% 0.4 
>40 g/day 12 92 % 
HBeAg Negative 44 84% 0.08 
Positive 54 60% 
AST" ,;;30 IU/1 22 81% 0.01 
31-60 lUll 38 76% 
>60 IU/1 38 48% 
Bilirubin" ;S; 12 j.tillOI/1 53 91% <0.001 
13-34 l'mol/1 35 56 % 
> 34 jLIDOlll 10 0% 
Albumin ;S;34 gil 22 32 % 0.003 
>34 gil 76 83 % 
Coagulation ;S;34 % 16 48% 0.02 
factors >34% 82 75% 
Ascites Absent 85 83% 0.004 
Present 13 23% 
Varices Absent 59 86% 0.002 
Present 39 48% 
Encephalopathy Absent 94 73% 0.005 
Present 4 0% 
*: tested for trend 
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Figure 1. Survival of 98 patienJ:s with HBsAg-positive cirrhosis. Curve obtained by 6-month 
interpolation of the Kaplan-Meier estimates. Numbers along the curve denote the number of 
patients at risk. 
HBeAg seroconversions occurred after treatment with a-interferon. No difference in survival 
was found for patients with a spontaneous or therapy induced HBeAg seroconversion. 
After multivariate analysis, ascites, serum bilirubin level and age remained as factors that 
were independently related to survival. The influence of each of these three variables is 
illustrated in figures 2a-c. Patients with ascites had a relative death rate (RDR) of 6.0 relative 
to patients without ascites (95% CI 1.8-19.5); patients with a higher bilirubin level had an 
RDR of 1.6 relative to those with a 50% lower level (95% CI 1.1-2.3); and older patients 
had an RDR of 2.4 relative to those who were 10 years younger (95% CI 1.7-3.3). All 
factors of less prognostic importance, according to the multivariate analysis, correlated with 
at least two of the three independent indicators of survival. 
After the analysis of the total group, we investigated survival for patients with compensated 
and decompensated liver disease (figure 3). Decompensation was defmed as the presence of 
ascites and/or jaundice (serum bilirubin of more than 34 !'moll!) and/or encephalopathy 
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and/or a history of variceal bleeding, at entry into the study, Decompensated liver disease 
was diagnosed in 21 patients, Fourteen of these patients died within three years, the other 
seven patients were still alive after 0.8 to 5.9 years of follow-up. The survival rate for 
patients with decompensated cirrhosis was 70% at 1 year, 35% at 3 years and 14% at 5 years 
(95% CI 48-93%, 12-58% and 0-31%, respectively). For the 77 patients with compensated 
cirrhosis the survival rate was still 84% at 5 years (95% CI 76-92%). 
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Figure 2. Survival of patients with HBsAg-positive cirrhosis in relaJion to the presence of 
ascites (A), the serum bilirubin level (B) and age (C). 
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Figure 3. Survival of HBsAg-positive patients with compensated or decompensated cirrhosis. 
For the group of patients with compensated cirrhosis, age and HBeAg status at entry were 
the only factors that significantly influenced the survival rate. The five-year survival 
probability was 72% for HBeAg-positive patients compared to 97% for HBeAg-negative 
patients (P=0.03; 95% CI 55-87% and 92-100%, respectively) (figure 4a). After adjustment 
for age the difference in survival between compensated patients with and without detectable 
HBeAg at presentation remained significant (P=0.04). The estimated actuarial HBeAg 
seroconversion rate at 1 and 5 years was 22% and 63%, respectively. For patients who 
showed clearance of HBeAg from serum, there was a 2.2 fold decrease in death rate (RDR 
0.45; 95% CI 0.1-2.1) compared to patients who remained HBeAg positive. The age-adjusted 
RDR after HBeAg seroconversion was 0.57 (95% CI 0.1-2.6). No difference in survival was 
found between patients with different HBeAg starus in the decompensated group (figure 4b). 
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Figure 4. Survival of HBsAg-positive patients with compensated (A) and decompensated (B) 
cirrhosis in relation to the HBeAg-status at entry. 
Discussion 
The results of this smdy show an estimated 71% five-year survival rate after histological 
diagnosis of HBsAg-positive liver cirrhosis in a predominantly white West-European 
population. Hepatocellular carcinoma and liver failure with or without variceal bleeding were 
the main causes of death. Comparable results were obtained in prognostic smdies on HBsAg-
positive cirrhosis in other geographical areas of the world with estimated five-year survival 
rates of 55% in the USA, 80% in Taiwan, 66% in Japan and 52% in Italy (13-16). It is 
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conceivable that both our own survival rate and those of others are somewhat pessimistic 
since most study centers function as regional hospitals where many tertiairy referrals are 
treated. 
In the present study, all investigated indicators of impaired liver function or portal 
hypertension - bilirubin, albumin, blood coagulation status, the presence of ascites or 
encephalopathy and evidence of esophageal varices - were strongly associated with survival, 
according to the univariate analyses. The incidence of both liver transplantation and 
concontitant vital infections (hepatits C, delta, HIV) was low and did not influence the 
outcome of survival in this study. After multivariate analysis age, ascites and total serum 
bilirubin remained as the most powerful prognostic indicators. A previous study of prognostic 
factors of HBsAg-positive cirrhosis selected age above 40 years, serum bilirubin above 1.5 
mg/dl (25 mmol/1), ascites and spider nevi as independent indicators of mortality (14). Other 
studies on the prognosis for patients with cirrhosis (viral, alcoholic or cryptogenic) also 
indicate that the strongest indicators of survival are parameters that relate to the synthetic 
function of the liver and the presence of portal hypertension (26-29)' We separately analyzed 
the survival rate for patients with compensated and decompensated cirrhosis, since the 
findings for the whole group may have been influenced by the selected inclusion of patients 
with an extremely poor prognosis who were referred to our deparnnent for liver 
transplantation or treatment of variceal bleeding. To defme decompensation of liver disease 
we selected four generally accepted criteria known to influence the survival of patients with 
liver disease (29). For patients with decompensated cirrhosis the five-year survival rate was 
only 14%. In contrast, patients with compensated cirrhosis exhibited a very good prognosis 
with a five-year survival rate of 84%. Interestingly, in the compensated group none of the 
patients (n=30) for whom follow-up was continued beyond the 5th year died in the 5 years 
thereafter (data not shown). 
Active HBV replication is associated with ongoing inflannnatory activity and progression of 
liver disease. HBeAg seroconversion, indicating a transition to viral latency, is' usually 
accompanied by biochentical and histological regression of liver disease activity (30-32). With 
the availability of antiviral agents, such as a-interferon, cessation of the viral replicating 
phase can be induced in about one-third of the patients (33,34). However, it is not yet known 
whether HBeAg seroconversion leads to improved survival for cirrhotic patients (30,35). 
Some authors state that the severity of the underlying liver histology at the time active viral 
replication ceases is critical for the final outcome (35). In the present study, in which all 
patients had sintilar histopathological diagnoses, patients without detectable HBeAg in the 
serum had a more favorable prognosis than those with HBeAg. This phenomenon was even 
more prominent among patients with compensated liver disease for whom there was a 
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significantly improved life expectancy for HBeAg-negative patients and a strong trend towards 
better survival after HBeAg seroconversion during follow-up. This significance of the HBeAg 
status did not disappear after adjustment for age. the only other factor that was indepently 
related to the survival of patients with compensated cirrhosis. For patients with 
decompensated cirrhosis, the HBeAg status did not influence the survival rate and it thus 
seems likely that there is a time point in the course of the disease when HBeAg 
seroconversion will no longer lead to an improved prognosis. 
These results imply that there is a strong indication for antiviral therapy in patients with 
HBeAg-positive compensated liver cirrhosis, whereas liver transplantation will rarely be 
indicated in view of the very good prognosis for this group. However, if hepatic 
decompensation occurs, liver transplantation appears to be the major therapeutic option to 
reduce the risk of death. The exact timing of surgery as well as measures to suppress viral 
replication to reduce the risk of reinfection of the graft remain to be determined. 
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Abstract 
In a European multicenter study 40 patients with HBeAg-positive chronic hepatitis B virus 
(HBV) infection were treated with 5 megaunits of lymphoblastoid a-interferon daily 
according to the following regimen: a 4-week primer course, 4 weeks of rest and a second 
course lasting 16 to 30 weeks. After 52 weeks of follow-up, a response (HBeAg 
seroconversion and HBV-DNA negativity) was observed in 22 patients (55%). HBsAg 
seroconversion occurred in 5 patients (12.5%). One patient exhibited a relapse for serum 
HBeAg and HBV-DNA after cessation of treatment. According to a response prediction 
model, the observed response rate was not related to the selection of patients likely to 
respond. 
The initial interferon course induced a reduction of the serum HBV -DNA and HBeAg 
levels of 87% and 18%, respectively, leading to a significantly lower level of viral 
replication activity at the start of the second longterm course compared to baseline. 
After 24 weeks of foiiow-up (week 16 of the second course), 19 (48%) patients exhibited 
a response, 13 (32%) a partial response (HBeAg <50% of initial level or HBV-DNA 
negative) and 8 (20%) no response. For 8 of the 13 partial responders treatment was 
stopped at week 24 and viral replication rebounded to pretreatment values. In the last 5 
partial responders prolongation of therapy up to week 38 led to a definite response and 
HBsAg seroconversion in 3 of the 5 patients. 
The results of this study suggest that both a short primer course and prolongation of 
therapy may help to enhance the response rate of a-interferon therapy for chronic hepatitis 
type B. 
26 
Introduction 
In patients with chronic hepatitis B virus (HBV) infection active viral replication is usually 
associated with continuing inflammatory activity and progression of liver disease. 
Transition to viral latency, as indicated by hepatitis B e antigen (HBeAg) seroconversion 
and clearance of serum HBV-DNA, is accompanied by biochemical and histological 
regression of liver disease activity (1-3). With the availability of a-interferon (IFN), 
termination of the viral replicating phase can be induced in about 30 to 40% of the 
patients (4-6). Usually a-IFN is given in a single continuous course. 
From a pilot study comparing the antiviral effect of a-IFN, acyclovir and a combination 
of a-IFN and acyclovir, it was concluded that combination therapy appears to be a highly 
promising treatment for chronic hepatitis B (7). Since more recent controlled studies have 
shown that acyclovir does not enhance the therapeutic effect of a-IFN alone (8), the 
results of the pilot study could also be interpreted as indicating that a second course of a-
IFN following short-term primer a-IFN therapy is more effective than a single course. 
Therefore we investigated the effect of intertnittent a-IFN treatment on termination of 
hepatitis B viral replication, measured by HBeAg seroconversion and HBV-DNA 
clearance from serum. 
Methods 
Patients and Treatment 
Forty-four patients from 6 European hospitals were enrolled in the study after central 
evaluation of their eligibility. At entry all patients had been seropositive for hepatitis B 
surface antigen (HBsAg) and HBeAg for at least 6 months. Histological evidence of 
chronic hepatitis was present in all patients who underwent a liver biopsy (n=43). Patients 
were excluded on grounds of the following criteria: age under 18 or over 70 years; 
presence of hepatitis delta antibodies in serum; antiviral or inunune modulatory therapies 
in the preceding 6 months; history or presence of decompensated liver disease (ascites, 
encephalopathy, variceal hemorrhage); pregnancy; impaired inununity, including 
seropositivity for human inununodeficiency virus with T4 cells < 400/mm3; inadequate 
levels of platelets ( < 70 x 109/l) or white blood cells ( < 3 x 1091!); recent drug or 
alcohol abuse; presence of significant other disease that might interfere with the study. 
The study was approved by the ethical committees of all participating centers and written 
informed consent was obtained from each patient who entered the study. 
Lymphoblastoid a-IFN (Wellferon, Wellcome, Beckeoham, U.K.) was given at a dose of 
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5 megaunits daily according to the following regimen: a 4-week primer course, a 4-week 
rest period and a second a-IFN course lasting 16 weeks; for 5 patients from Rotterdam 
the duration of the second course was prolonged up to 30 weeks. Patients were taught to 
self-administer a-IFN subcutaneously. During the first 4 days of a-IFN therapy indome-
thacin or paracetamol was given to suppress early side-effects. a-IFN treatment was 
discontinued in the event of absence of HBeAg on two successive occasions or intolerable 
side-effects. Follow-up began at the start of therapy and was continued for 52 weeks. 
Clinical and Laboratory Evaluation 
Patients were seen, and if indicated examined, at the outpatient clinic every 2 to 4 weeks 
during treatment and every 4 to 8 weeks during the period thereafter. Laboratory 
assessment was performed every 2 weeks during the treatment period and every 4 to 6 
weeks after discontinuation of therapy. On these occasions routine hematological studies 
were performed and serum markers of viral replication (HBeAg and HBV -DNA) and 
aspartate aminotransferase (AST) activity were measured. Every 3 months additional 
biochemical and virological measurements including the prothrombin time and the levels 
of alanine aminotransferase, albumin, bilirubin, HBsAg, and antibodies against HBsAg as 
well as HBeAg were performed. Liver biopsies were taken within 6 months of entry to the 
study for histological assessment. 
All virological parameters were determined centrally at the Rotterdam hepatitis laboratory. 
HBsAg was assessed using a commercial radioimmunoassay kit (Abbott, ill., USA). 
HBeAg was measured quantitatively using a radioimmunoassay (Abbott, Ill., USA). For 
quantification a PIN ratio (counts of patient sample/counts of negative control sample) was 
determined for each patient in a fixed serum dilution. HBeAg seroconversion was defined 
as a PiN ratio under 2.1 for undiluted serum from 2 consecutive blood samples. HBV-
DNA was measured by a liquid hybridization assay using an iodine-125 probe (Abbott, 
Ill., USA). Antibodies to hepatitis C virus were determined, retrospectively, by enzyme 
immunoassay (Abbott, Ill., USA); positive results were confirmed by a recombinant 
immunoblot assay (Ortho Diagnostics Systems, USA). Routine serobiochemical tests were 
performed using automated techniques (Coulter, Tecbnicon, NY, USA). 
The criteria for response to treatment were: HBeAg seroconversion and serum HBV-DNA 
negativity. The criteria for partial response to treatment were: a decrease in serum HBeAg 
of 50% or more of the initial level or serum HBV-DNA negativity with sustained HBeAg 
positivity after 24 weeks of follow-up. 
To analyze whether the response rate was related to treatment modification or selection of 
patients, the actual response was compared with a predicted response that was obtained 
28 
with a response model developed by Brook et al. (9). The prediction of response was 
based on pretreatment AST levels, the presence of a history of acute hepatitis and HIV-
antibody starus. 
Statistics 
Differences in dichotomous and other discrete variables were analyzed by the Fisher exact 
and Chi-square tests, respectively. For continuous variables medians were used because 
the results lacked normal distribution. The two-sample Wilcoxon rank sum test was used 
to analyze unpaired observations and the Wilcoxon signed rank test to analyze paired 
observations. 
Results 
Four of the 44 patients were withdrawn from the study. Two patients were found to be 
HBeAg negative at the start or within one week of treatment while pre-entry assessments 
were positive. Two patients were lost to follow-up: one withdrew from treatment after 2 
weeks for reasons unrelated to the study protocol and one patient failed to comply with the 
protocol after cessation of therapy. 
Patient cbatacteristics at entry are shown in table I. Of the 40 patients who were 
analyzed, one was serum HBV-DNA negative on entry to the study. 
Response 
A response to treatment (HBeAg seroconversion and serum HBV-DNA negativity) was 
observed in 22 of the 40 patients (55%; 95% confidence interval (CI) 40-70%). Five 
patients (12.5%; 95% Cl 4-27%) became negative for HBsAg. Sustained AST 
normalization occurred in 16 out of 19 responders with elevated AST levels on entry to 
the study. Fignre 1 shows the timing of elimination of viral parameters and sustained AST 
normalization in the response group. All but one patient exhibited the response while on 
a-IFN therapy. A characteristic sequence in clearance of HBV-DNA and HBeAg and then 
normalization of AST levels was observed for the majority of the responders. One 
responder showed a relapse for serum HBeAg, HBV-DNA and AST 20 weeks after 
cessation of therapy. Of the 18 nonresponders, 5 exhibited normalization of AST levels 
and 6 became- transiently- serum HBV-DNA negative. 
Differences in characteristics between responders and nonresponders are shown in table 1. 
The pretreatment serum HBV-DNA level was lower and the AST level higher in the 
response group. Also the duration of HBsAg positivity was shorter and the presence of 
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Table 1. Patient characteristics at entry into the study. 
Total Group Response Nonresponse 
n=40 n=22 n=18 
Age (yr) 38.5 (18-67) 42 (27-67) 37 (18-56) 
Male/Fenta!e 32/8 17/5 15/3 
Homo/Heterosexual 9/31 3/19 6/12 
HBsAg duration· (mo) 27 (6-132) 14 (6-132) 33 (12-96) 
History acute hepatitis 2 1 1 
Histology: CPH 8 2 6 
CAH 20 12 8 
cirrhosis 11 8 3 
Aoti-HCV positive 1 1 0 
H1V -status: negative 38 21 17 
unknown 2 1 1 
HBeAg" (P/N ratio) 12.4 (2.2-18.8) 13.4 (2.5-18.8) 11.9 (2.2-16.4) 
HBV-DNA" (pg/ml) 102 (1-1001) 79 (1-730) 127.5 (3-1001) 
HBV-DNA < 50 pg/ml 11 8 3 
51-100 9 6 3 
101-300 13 5 8 
> 300 7 3 4 
AST" (U/1) 57.5 (15-475) 66.5 (15-475) 51.5 (16-113) 
AST < 30 U/l 7 3 4 
31-60 14 7 7 
61-100 11 5 6 
>100 8 7 1 
* median (range) 
AST normal < 30 U/1; HBV-DNA cut-off: 1.5 pg/ml; HBeAg cut-off: PIN ratio 2.1 
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Figure 1. Cumulative percentage of clearance of serum HBV-DNA, HBeAg 
serocorrversion, normalization of serum AST and HBsAg seroconversion for patients who 
responded to therapy (n=22). 
cirrhosis was more prominent in responders. However, no statistical difference between 
responders and nontesponders was found for any of these parameters. 
According to the Brook model, a response was predicted for 14 of the 40 patients (35%; 
95% CI 20-50%), with a positive predictive value of 79% and a negative predictive value 
of 58%. Compared to this prediction the actual response rate of 55% was significantly 
higher (P = 0.03). 
Intennittent Treatment 
Changes in serum AST, HBV-DNA and HBeAg values ate shown in figure 2. The primer 
a-IFN course reduced HBV-DNA and HBeAg levels by 87 and 18 percent, respectively, 
but the decrease did not continue during the 4 weeks without therapy. Nevertheless, at the 
start of the second a-IFN course, the serum HBeAg aod HBV -DNA levels were signifi-
cantly lower compared to baseline values. No difference was found in the AST levels at 
the start of the two courses; however both courses seemed to induce a peak of AST values 
that often preceeds a response to therapy. 
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Figure 2. Median levels of HBeAg, HBV-DNA and ASTin serum (n=40). 
Prolonged Treatmem 
After 24 weeks of follow-up (week 16 of the second course), 19 (48%; 95% CI 32-63%) 
patients exhibited a response, 13 (32%; 95% CI 18-47%) a partial response and 8 (20%; 
95% CI 8-32%) a defmite nonresponse. For 8 of the 13 partial responders, treatment was 
stopped at 24 weeks. After cessation of therapy the serum HBeAg and HBV-DNA levels 
in these patients rebounded to baseline levels (figure 3). For the last 5 partial responders 
a-IFN therapy was prolonged up to week 38. Three of these 5 exhibited an additional 
response during prolonged therapy (figure 3), and all 3 showed HBsAg seroconversion 
shortly after the response. 
Side Effects of Imerjeron 
During the first week of the initial a-IFN course, a transient flu-like syndrome with fever, 
chills and myalgia was observed in nearly all of the patients. At the beginning of the 
second a-IFN course, the majority again reported these symptoms but to a lesser intensity. 
The predominant adverse effects after the first days of therapy were fatigue (73%), 
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Figure 3. Serwn HBeAg and HBV-DNA levels in a partial responder treated until 24 
weeks (protocol therapy) and in a partial responder treated until 32 weeks (prolonged 
therapy) who exhibited an additional response. 
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myalgia (60%), anorexia (43%), irritability (30%) and bair loss (15%). Two patients 
developed an acute psychosis: the first, who had just finished therapy, required intensive 
psychiatric care for 2 weeks; the second, who had been treated with a-IFN for 3 weeks, 
feU and fractured the acetabulum. Another patient had a generalized seizure after 4 and 11 
weeks; he was put on anticonvulsive medication and a-IFN was tapered to 1.25 megaunits 
daily. Side effects led to dose reduction in 11 subjects (28%). The reasons for dose 
reduction were fatigue in 6 cases, thrombocytopenia in 2, neurotoxicity in 2 and 
leukopenia in 1. Four (36%) out of these 11 patients exhibited a response. 
Discussion 
In recent years several strategies have been tested to enhance the efficacy of a-IFN 
therapy for chronic hepatitis B. None of these strategies - including additional therapy 
with agents such as gamma-interferon, prednisone, acyclovir or adeninide arabinoside 
(5,8,10-12) - has proved to be more beneficial than a standard a-IFN course of 12-16 
weeks. 
In this uncontroiied pilot study we investigated the effect of prolonged intermittent a-IFN 
therapy in 40 patients. Fifty-five percent of the patients responded with HBeAg 
seroconversion and loss of serum HBV-DNA. HBsAg seroconversion occurred in 12.5% 
of all treated patients and in almost 25% of those who responded. A majority of the 
responders demonstrated a characteristic sequence in loss of serum HBV-DNA and 
HBeAg foiiowed by normalization of the AST value. HBeAg seroconversion was often 
heralded by a rise in transaminase activity and loss of HBV-DNA. Stiii, in 6 patients 
HBV-DNA disappeared from the serum but quickly reappeared after discontinuation of 
therapy, indicating that persistent absence of HBeAg is the best indicator for termination 
of the viral replicating phase. 
Although several differences in pretreatment characteristics of responders versus 
nonresponders were observed, none of them was found to be significant. The predicted 
response rate, based on a combination of pretreatment factors (9), was significantly lower 
(35%) than the actual response rate (55%). This result suggests that the high response rate 
was not caused by selection of patients likely to respond but by the treatment modifica-
tion. 
It is difficult to determine the contribution of intermittent therapy to the high response rate 
obtained in this uncontroiied study. The rationale for the initial 4-week course was to 
decrease viral replication and increase inflammatory activity before the start of the 
Iongterm course, thereby enhancing the possibilty of response to therapy. At the start of 
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the second a-IFN course, viral replication, as monitored by serum HBV-DNA and HBeAg 
levels, was indeed significantly lower compared to baseline values. In addition, both a-
IFN courses induced transient elevation of aminotransferase levels. Therefore both courses 
could have induced a response in some patients and the double transaminase peak could 
thus be indicative of early and late responders. These interesting observations certainly 
justify further evaluation of intermittent treatment in a controlled setting. 
Close on-line monitoring of the effects of a-IFN on viral replication revealed that in 
several patients HBeAg and HBV-DNA serum values decreased continuously and were 
almost negative when treatment was stopped (week 24) at which point a relapse occurred. 
Therefore, we decided to offer prolonged treatment to the remaining patients who 
approximated a response at the end of the scheduled therapy (partial response). For 3 of 
the 5 partial responders this approach led to a definite response and subsequently to 
HBsAg seroconversion. Of the 2 patients who did not respond to prolonged treatment one 
had extremely high initial serum HBV-DNA levels ( > 1000 pglml), while both patients 
had near normal AST levels at entry. These features - low serum aminotransferase and 
high HBV-DNA levels - have been suggested to interfere with the response to a-IFN 
treatment (4,5,9,13). Onr fmdings indicate that prolonging a-IFN therapy may increase 
the HBeAg and HBsAg seroconversion rates in the subset of patients that partially respond 
to standard interferon treatment. To select patients eligible for treatment prolongation, 
close monitoring of quantified levels of HBeAg and HBV -DNA is essential. 
From the literature it is not clear whether prolongation of therapy beyond 4 months yields 
a higher response rate. Prolonged therapy can further decrease HBV replication which 
may trigger the cellular immune response leading to the hepatocytotoxic reaction that 
eradicates viral replication (14). In most parts of the world the standard duration of 
therapy is considered to be 12-16 weeks, usually leading to a response rate of 30-40% (4-
6,15). a-IFN has been given for 24 weeks or longer in a few - mainly Mediterranean -
studies (response rates 26% to 70%) (16-18). A controlled ttial comparing 12 to 24 weeks 
of treatment failed to demonstrate any beneficial effect of the prolonged therapy (19). 
However, the outcome of that study was markedly iofluenced by a lack of compliance (8 
of the 20 patients withdrew from the longer course). In the present study none of the 
patients had to withdraw from therapy because of side effects, irrespective of the length of 
treatment. Both the intermittent treatment schedule and intensive patient monitoring with 
mental support may have contributed to the good compliance. Nevertheless, 3 of our 
patients had major neuro-psychiatric side effects (psychosis, seizures). Future studies 
might elucidate whether these serious side effects relate to dose and/ or duration of the a-
IFN treatment. 
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In summary, prolonged intermittent a-IFN therapy resulted in HBeAg seroconversion and 
serum HBV-DNA negativity in 55% and in HBsAg seroconversion in 12.5% of the 
patients. The high rate of induced viral latency was probably related firstly to the short 
initial a-IFN course that reduced viral replication significantly before the start of the 
second longterrn course and secondly to prolongation of therapy in partial responders 
which induced additional HBeAg seroconversion. 
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Abstract 
Alpha-interferon ("-IFN) therapy leads to HBeAg seroconversion in only one-third of the 
patients with chronic hepatitis B. In an attempt to increase the seroconversion rate we 
investigated the combination of "-IFN and zidovudine in a subset of patients with a 
presumably low response rate for "-IFN monotherapy. In a double-blind controlled trial 
24 HBeAg-positive patients were randomized to receive lymphoblastoid "-IFN in doses 
increasing to 5 MU s.c. daily, combined with zidovudine given orally in doses increasing 
from 500 to 1000 mg or placebo daily for 16 weeks. Treannent effects were monitored by 
quantitative assessment of HBV-DNA, HBeAg and HBV-DNA polymerase. Six months 
after termination of therapy 1112 (8%; 95% CI 2-39%) patients treated with "-IFN plus 
zidovudine and 2/12 (17%; 95% CI 2-48%) patients from the control group exhibited a 
response (HBeAg seroconversion). All patients remained HBsAg positive. The only 
responder of the "-IFN-zidovudine group relapsed after cessation of therapy so that none 
of the zidovudine-treated patients were HBeAg negative at the end of follow-up. No 
significant difference in AST or any of the virological markers was observed between the 
2 groups during the entire course of the stody. Adverse effects (anemia, leukopenia) 
necessitated a reduction in the dose of zidovudine in 50% and "-IFN in 42% of the pa-
tients treated with "-IFN plus zidovudine; in the control group these rates were 0% for 
placebo and 8% for "-IFN. In conclusion, the antiviral effect of "-IFN in chronic 
hepatitis B was not enhanced by additional zidovudine treannent. The combination therapy 
induced considerable side effects leading to dose reduction for both zidovudine and "-IFN. 
For combination therapy with a-IFN, oral nucleoside analogues with a more potent 
antiviral effect and less toxicity than zidovudine should be developed. 
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Introduction 
Alpha-interferon (a-IFN) is currently the most effective therapy for chronic hepatitis B 
virus (HBV) infection. Nevertheless only one-third of the patients respond to this 
treatment with virological and biochemical remission of the disease (1-3). One of the ways 
to enhance the response rate for a-IFN is combination therapy with nucleoside analognes. 
Zidovudine (3'-azido-3'-deoxythymidine, AZT) has proven to be a potent inhibitor of the 
reverse transcriptase activity of the human immunodeficiency virus (HIV) (4,5). Since 
reverse transcriptase activity also plays an important role in the HBV replication cycle, 
zidovudine would appear to be a promising candidate for combination therapy with a-IFN 
which attacks the virus via other steps in the HBV replication cycle and via the cellular 
immune system. 
After both in vitro and in vivo studies demonstrated that zidovudine caused a marked 
decrease in HBV replication, as monitored by HBV-DNA polymerase (6), we initiated a 
randomized controlled trial to compare the antiviral effect of a-IFN alone with that of the 
combination of a-IFN and zidovudine. 
Patients and Methods 
Twenty-four patients were randomized to receive a-IFN therapy combined with either 
zidovudine or placebo. The inclusion criteria were serum hepatitis B surface antigen 
(HBsAg) positivity for at least 12 months, histological evidence of chronic hepatitis and 
the presence of serum hepatitis B e antigen (HBeAg) for at least 6 months. Since the 
toxicity profile of zidovudine was not completely known at the time of the design of the 
study we were only permitted to treat patients who exhibited at least one of the following 
characteristics: previous nonresponse to a-IFN, anti-HIV positivity and/or the presence of 
cirrhosis. Patients were excluded for the following reasons: age below 18 or above 65 
years; presence of antibodies against the hepatitis delta virus in serum; low hemoglobin 
level ( < 7 mmol/1), thrombocyte count ( < 100 x 109/1) or leukocyte count ( < 3 x 109/1); 
anti-HIV seropositivity with a CD4 cell count below 400 per ml; decompensated liver 
disease (ascites, albuntin < 30 gil, encephalopathy, history of variceal bleeding); 
pregnancy; recent drog or alcohol abuse; antiviral or immunosuppressive therapy in the 6 
months prior to enrollment; presence of other significant diseases which might interfere 
with completion of the study. 
Lymphoblastoid a-interferon (Wellferon, Wellcome, Beckenham, UK) was given subcuta-
neously to all patients according to an increasing dose schedule of 1.5 ntillion units daily 
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for 4 weeks, 3 million units daily for 8 weeks and 5 million units daily for 4 weeks. 
Patients were carefully instructed to self-administer the a-IFN. Simultaneously with the 
16-week a-IFN course, zidovudine or placebo (Wellcome, Beckenbam, UK) was 
administered orally in a dose of 250 mg twice daily for the first 8 weeks and 500 mg 
twice daily for the last 8 weeks. 
All patients were followed in the hepatology outpatient clinic of our hospital which has a 
tertiary referral function. Twenty-nine consecutive patients were eligible for the study; 
five were excluded during the pretreatment 6-week screening period: two decided not to 
participate, one HIV-infected patient exhibited a drop in the CD4 cell count under 400/ml, 
one patient cleared serum HBeAg and in another the HBeAg level dropped to borderline 
positivity. 
For randomization a serial number that corresponded to a set of boules containing either 
zidovudine or placebo capsules was randomly assigned to each consecutive patient who 
started therapy. Investigators and patients were unaware whether zidovudine or placebo 
was given. To exclude any indication of the dose of zidovudine, all patients were given 2 
capsules twice daily during the entire treatment period. The randomization code was 
prepared by the Wellcome Foundation (Beckenbam,UK), kept in a sealed envelope by the 
hospital pharmacist and opened after the last patient had completed therapy. All randomi-
zed patients gave written informed consent before participation. The study was approved 
by the hospital committee of medical ethics. 
Patients were seen by a physician in the hospital at monthly intervals and followed for 6 
months after cessation of therapy. Blood samples were obtained weekly during therapy 
and monthly in the period thereafter. HBeAg, HBV-DNA polymerase, aspartate amino-
transferase (AST), hemoglobin and leukocytes were assessed in all samples. The HBV-
DNA level was determined monthly. Additional routine hematological, biochemical and 
virological tests were performed at entry and at the termination of both therapy and 
follow-up. Patients were asked to undergo a liver biopsy within 6 months prior to the start 
of therapy and at the end of follow-up. The biopsies were examined under code by a 
single experienced pathologist who was unaware of the chronological order of the biopsies 
and the design of the trial. Histological scoring was based on the histological activity 
index, as described by Knodel! (7). 
The hematological, chemical and virological measurements were each performed in a 
single laboratory. HBsAg and antibodies against HBsAg, HBeAg, hepatitis C and hepatitis 
delta virus were assessed by enzyme immunoassays (Abbott, Ill, USA): positive results for 
hepatitis C antibodies were confirmed by a recombinant immunoblot assay (Orlho 
Diagnostic Systems, USA). HBeAg, HBV-DNA polymerase and HBV-DNA were 
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determlned quantitatively. The HBeAg level was expressed as a PIN ratio (counts of 
patient sample/counts of negative control sample) using a radioimmunoassay kit (Abbott. 
ill, USA). For each patient a fixed serum dilution was used throughout the study. HBeAg 
seroconvetsion was defmed as a PIN ratio below 2.1 for undiluted serum from 2 consecu-
tive blood samples. The HBV -DNA polymerase activity was measured as described by 
Fang, using a modification of the thymidine-methyl-5' -triphosphate (3HdTTP) elution 
technique (8). HBV-DNA was assessed by a solution hybridization assay which utilizes a 
125I labelled probe (cut-off 1.7 pg/mi; Abbott, lll, USA). All hematological and bioche-
mical markers were assayed by means of automated techniques (Technicon, NY, USA). 
The criteria for response to therapy were HBeAg seroconversion with serum HBV-DNA 
and HBV-DNA polymerase negativity. All other patients were defined as nonresponders. 
Where data lacked a normal distribution, medians were used to denote continuous 
variables. The Wilcoxon rank sum and signed rank tests were used for comparison of 
unpaired and paired observations, respectively. Dichotomous variables were analyzed with 
the Fisher exact test. Differences with a P-value below 0.05 were considered to be 
significant (two sided testing). 
Results 
The patient characteristics for the two treatment groups were weii matched at the start of 
therapy (table 1). All patients had detectable serum HBV-DNA and HBV-DNA polymera-
se levels, except for two (one in each treatment group) who were HBV-DNA negative on 
enroiiment in the study; both patients were included in the study because they had stable, 
positive HBeAg levels. Co-infection with hepatitis C was not used as an exclusion crite-
rion since the anti-HCV test was not available at the initiation of the study; retrospective 
screening revealed that one patient was anti-HCV positive. 
All randomized patients completed the entire foiiow-up period of the study. A response 
was found for 1 (8%;95% confidence interval 2-39%) patient treated with a-IFN plus 
zidovudine and 2 (17%;95% confidence interval 2-48%) treated with a-IFN plus placebo. 
The zidovidine-treated patient exhibited a relapse for HBeAg, HBV-DNA and HBV-DNA 
polymerase after therapy was stopped. All patients remained seropositive for HBsAg. The 
tinting of response and other virological events for the investigated groups is illustrated in 
fignre 1. Clearance of serum HBV-DNA and HBV-DNA polymerase but continued 
presence of HBeAg was found for 2 and 4 patients, respectively, of the a-IFN-zidovudine 
group and 1 and 2 patients, respectively, of the control group. In most cases these 
markers reappeared after cessation of treatment. 
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Table 1. Patient characteristics 01 the start of therapy. 
Male/Female 
Age (yr) 
Caucasian/Oriental 
Fletero/F!omosexual 
Duration .FIBsAg positivity• (yr) 
F!istory acute hepatitis yes/no 
Previous a-IFN therapy yes/no 
Anti-.HlV neg/pos/unknown 
Anti-F!CV neg!pos 
.FIBV-DNA• (pglml) 
.FIBeAg· (PIN ratio) 
.FIBV-DNA polymerase (PIN ratio) 
AST• (U/1; normal< 30) 
AST elevated/normal 
CPF!!CAF!I Cirrhosis 
*: median (range) 
a-interferon 
zidovudine 
(n=12) 
1/1 
5 (25-64) 
1/1 
0/2 
4.8 (1.3-9.9) 
1/11 
9/3 
111110 
1111 
108 (1-505) 
11.5 (4.4-18.4) 
15.5 (2-290) 
44 (20-109) 
9/3 
4/5/3 
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a-interferon 
placebo 
(n=12) 
11/1 
34.5 (23-58) 
12/0 
6/6 
4.1 (1.0-8.0) 
1111 
7/5 
9/2/1 
12/0 
85 (1-819) 
9.6 (3.4-17.8) 
18.5 (2-510) 
46 (22-180) 
10/2 
4/3/5 
% 
SO SOOmg 
1000mg 
SO .5mu 3.0mu 
S.Omu 
40 
30 
20 
10 
AZT 
OFN 
HBV-DNA 
polymerase 
0'-'-'---~--~---~---~--~ 
40 
30 HBV-DNA 
20 
30 
HBeAg 
20 
weeks 
Figure L Percentage of patients treated with a-IFN in combination with zidovudine (--- ; 
n=12) or placebo (---; n=I2) who exhibited dearance and/or reactivation of HBeAg, 
HBV-DNA and HBV-DNA polymerase during follow-up. 
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During the treatment period the median decrease in HBV-DNA was 71% and 67%, 
HBeAg 29% and 20%, and HBV-DNA polymerase 62% and 71% for the a-IFN-zidovu-
dine and a-IFN-placebo groups, respectively; these results indicate a significant decrease 
in these viral markers for both groups (figure 2). However, after therapy all 3 parameters 
rebounded to pretreatment levels among the majority of the patients, leaving no significant 
difference between the initial virological levels and those at the end of the observation 
period. Of the 19 patients with an elevated AST level at entry only the 2 permanent 
responders and 1 nonresponder treated with a-IFN and zidovudine exhibited sustained 
normalization of AST. In 2 patients from each treatment group - all nonresponders - the 
AST level rose to more than twice the initial value during therapy. Comparison of the two 
therapy groups did not show a significant difference in AST or any of the quantified 
virological markers during the entire course of the study (figure 2). 
The results of histological scoring are shown in table 2. One patient from each therapy 
group refused to undergo the second biopsy. A decrease in the histology activity index 
was found for 3 (27%) patients treated with zidovudine and 4 (36%) treated with placebo, 
including the 2 persistent responders. No significant difference was found either within or 
between the two groups in initial and posttreatment histological scores. 
Adverse effects of a-IFN and/or zidovudine therapy were observed in the majority of the 
patients (table 3). Despite the low initial dose of a-IFN most patients experienced flu-like 
disease with fever, fatigue and myalgia, primarily during the first 2 weeks of treatment. 
The predominant side effect later in the course of therapy was fatigue. Almost all adverse 
effects were more common among patients treated with a-IFN and zidovudine. In 
particular anemia and leukopenia were pronounced in this group; in 2 patients the anemia 
was symptomatic and necessitated blood transfusions (hemoglobin < 5. 0 mmol/1). One 
(HlV-positive) patient from the a-IFN-placebo group experienced epileptic insults in the 
lOth and 16th weeks of therapy; after the first seizure a-IFN was continued because no 
clear relationship between therapy and insult was suspected (9). After the end of the 
observation period hepatocellular carcinoma was diagnosed in one patient while another 
died of a variceal hemorrhage. Both patients had received a-IFN plus zidovudine; 
however a direct relation between these serious events and the treatment regimen appears 
unlikely. For a total of 9 patients the dose of zidovudine and/or a-IFN had to be reduced 
(table 3): in 4 cases zidovudine was reduced, all because of anemia; in 3 a-IFN was 
reduced, all because of leukopenia; and in 2 both zidovudine and a-IFN were reduced 
because of leukopenia with anemia or thrombocytopenia. The time of dose reduction 
ranged from 8 to 14 (median 12) weeks of therapy for zidovudine and from 8 to 13 weeks 
(median 12) for a-interferon; after the dose reduction zidovudine was discontinued in 4 
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Figure 2. Median levels of HBeAg, HBV-DNA, HBV-DNA polymerase and aspartate aminotransferase (AST) for chronic hepatitis B patients 
treated with a-/FN in combination with zidovudine (a--o; n=J2) or placebo (*------*; n=l2). 
Table 2. Histological scoring of serial liver biopsy specimens before treatment and at the 
end of follow-up. Results are denoted as mean ± S.D.; both groups consisted of 11 
patients. 
a-interferon a-interferon 
zidovudine placebo 
pretreatment end follow-up pretreatment end follow-up 
Piecemeal necrosis 2.0 ± 1.2 2.3 ± 1.3 2.2 ± 1.4 1.8 ± 1.1 
Focal necrosis 0.9 ± 0.8 1.2 ± 0.6 1.1 ± 0.7 1.2 ± 1.2 
Portal inflammation 2.5 ± 0.9 2.3 ± 1.0 2.4 ± 0.9 2.0 ± 1.1 
Fibrosis 2.2 ± 1.3 2.7 ± 1.5 2.7 ± 1.2 3.2 ± 0.9 
Total score 7.7 ± 3.1 8.3 ± 3.4 7.8 ± 3.8 8.1 ± 3.7 
patients and a-IFN therapy in none due to persisting adverse effects. Reduction of the a-
IFN dose was associated with a diminished decrease in HBV-DNA and HBeAg (median 
decline of 40% for HBV-DNA and 17% for HBeAg after a-IFN dose reduction versus 
71% (P=0.23) and 32% (P=0.06), respectively, for those on full dose a-IFN) during 
therapy. The percentage decrease in HBV-DNA, HBeAg and HBV-DNA polymerase for 
those who underwent zidovudine dose reduction was similar to that found for patients on 
full dose therapy. 
Discussion 
Many srudies have indicated that a-IFN can induce a transition from active viral replicati-
on to virus latency in 30 to 40% of the patients with chronic hepatitis B (1-3). One of the 
methods used in the search for more effective therapy is to combine a-IFN with antiviral 
agents that act on different steps of the replication cycle of HBV. 
In the present randomized placebo-controlled trial of a-!FN and zidovudine combination 
therapy we could not find an additional antiviral effect of zidovudine. The HBeAg sere-
conversion response was low both among patients treated with a-IFN plus zidovudine 
(8%) and those receiving a-IFN plus placebo (17%). All responders remained positive for 
HBsAg and for HBV-DNA measured by the polymerase chain reaction. Quantitative 
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Table 3. Side effects and consequential dose reductions of a-interferon and/or zidovudine 
therapy. 
Clinical: 
Fatigue 
Flu-like symptoms 
Apathy /Depression 
Weight loss (> 5%) 
Gastrointestinal symptoms 
Dizziness 
Laboratory: 
Anemia (Hb < 7.0 mmol/1) 
Leukocytopenia ( < 3.0*109/1) 
Thrombocytopenia ( <70*109/l) 
Dose reductions due to side effects: 
a-interferon 
zidovudine/placebo 
a-interferon 
zidovudine 
(n=12) 
10 (83%) 
9 (75%) 
5 (42%) 
5 (42%) 
4 (33%) 
3 (25%) 
6 (50%) 
9 (75%) 
2 (17%) 
5 (42%) 
6 (50%) 
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a-ID.terferon 
placebo 
(n=12) 
8 (67%) 
8 (67%) 
4 (33%) 
1 (8%) 
1 (8%) 
0 (0%) 
0 (0%) 
4 (33%) 
2 (17%) 
1 (8%) 
0 (0%) 
analysis of the virological parameters revealed a significant decrease in HBeAg, HBV-
DNA and HBV-DNA polymerase during therapy in both the a<-IFN plus zidovudine and 
the a<-IFN monotherapy group. However, no significant difference in these markers was 
observed between the two groups. 
There are two notable explanations for the overall low response in this smdy. Firstly, all 
patients included were either cirrhotic, anti-HIV positive and/or previous nonresponders to 
a<-IFN therapy; in particular the latter two characteristics are known to reduce the 
response rate for a<-IFN therapy (10-12). Secondly, the a<-IFN dose of 1.5 to 3 MU daily 
during the frrst 3 months of therapy might have been suboptimal. Several recent smdies 
have demonstrated that doses of at least 30 MU per week, administered either daily or 
thrice weekly, lead to higher HBeAg seroconversion rates than low-dose regimens (1,13). 
In spite of the low number of HBeAg seroconversion and the relatively small number of 
patients investigated, the comparable response rates and the similarity of the curves for all 
quantified virological markers for the two investigated groups are highly suggestive of a 
lack of additional HBV inhibitory effect of zidovudine. 
The rationale to smdy combination therapy consisting of zidovudine with a<-IFN is thst 
these compounds interfere in the HBV replication cycle at different sites. Zidovudine 
inhibits the DNA polymerase associated reverse transcriptase activity while a<-IFN - in 
addition to its innnunomodulatory effects - interferes primarily with viral protein synthe-
sis. Furthermore zidovudine can be administered orally and therefore allows monitoring 
on an outpatient basis. The lack of an additional HBV inhibitory effect of zidovudine, as 
found in the present smdy, does not agree with previous in vitro smdies in which a clear 
inhibitory effect of zidovudine-triphosphate on HBV-DNA polymerase activity was found 
nor with in vivo studies in which zidovudine therapy (800-1200 mg per day) resulted in a 
reduction of HBV-DNA and HBV-DNA polymerase in immunocompetent chronic REV-
infected patients (6,14). More in accordance with the results of the present smdy is the 
fact that in the hepatitis B duck model 1.5-15 mg/kg zidovudine per day failed to induce a 
suppression of DHBV replication (15). Other recent studies in which HBV patients were 
treated with zidovudine either with or without a<-IFN also could not show a beneficial 
effect of zidovudine on the HBV infection (16-19). Unlike our trial these smdies were 
uncontrolled and only included patients with a concurrent symptomatic HIV infection. 
The design of the smdy, i.e. to start with a low dose of a<-IFN that was gradually increa-
sed, was chosen to avoid a dangerous inflammatory exacerbation in patients with cirrhosis 
(20) and also to reduce the risk of severe bone marrow depression in those treated with a-
IFN and zidovudine. Our concern about side effects in the combination group was 
confirmed by the dose-limiting toxicities that occurred predominantly in the last month of 
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therapy when high doses of a-IFN and zidovudine were given. The severe anemia and 
leukopenia which only occurred in the a-IFN-zidovudine group indicates that a synergistic 
bone marrow-suppressing effect of a-IFN and zidovudine is probable (21). Similar 
adverse effects of a-IFN-zidovudine combination therapy were recently observed in mY-
infected patients with Kaposi sarcoma. The maximum tolerated dose for these patients was 
approximately 800 mg zidovudine and 5 MU a-IFN per day (22). In our patients additio-
nal toxic effects may have been generated by a delay in the biotransformation and clea-
rance of zidovudine due to limited hepatic function (23). 
So far, combination of a-IFN with other antiviral agents has induced considerable side 
effects and has not proven to be more effective than a-IFN alone (24-26). Nevertheless, 
nucleoside analogues and a-IFN interfere with HBV replication through different 
inhibitory mechanisms and in theory their combination could thus lead to a synergistic 
antiviral effect. On the other hand since nucleoside analogues may affect the intmune 
system, they could potentially reduce the important intmuooregulatory properties of a-
IFN. Moreover, it is essential to avoid the problem - as encouotered in the present study -
of a combination therapy that is so toxic that the dose of not only the nucleoside analogue 
but also a-IFN has to be reduced. 
In summary, we could not find an additional antiviral effect when zidovudine was given in 
combination with a-IFN therapy to chronic HBeAg-positive HBV -infected patients. 
Patients uodergoing the .combination therapy exhibited more dose-limiting side effects of 
both zidovudine and a-IFN than those on a-IFN monotherapy. In subsequent clinical 
studies to elucidate the antiviral effect of combination therapy, a-IFN should only be 
combined with antiviral agents which have demonstrated optimal efficacy and very low 
toxicity in HBV replication models. 
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Abstract 
In chronic hepatitis B transition from active replication to viral latency (HBeAg serocon-
version) usually leads to remission of the disease. Alpha-interferon (IFN) therapy induces 
HBeAg seroconversion in about one-third of the patients, thus leaving the majority of 
patients with persistent disease. 
Eighteen chronic hepatitis B patients who did not respond (HBeAg seroconversion and 
clearance of HBV-DNA) to an initial 16-week course of a-IFN subsequently received o:-
IFN again after at least 6 months of no therapy. The repeated therapy consisted of 1.5 - 5 
MU lymphoblastoid a-IFN daily for 16 weeks. Treatment effects were monitored by 
quantitative measurement of HBeAg and HBV-DNA. To analyze whether the results were 
related to patient characteristics known to affect the response to initial treatment, a 
predicted response rate, based on pretreatment factors, was determined. 
After a follow-up of 52 weeks, 2 of the 18 patients (11 %) had responded to therapy. Two 
additional patients became HBV-DNA negative with sustained HBeAg positivity. All pa-
tients remained HBsAg positive. According to the pretreatment parameters, a response 
was predicted for 9 of the 18 patients (50%). This predicted response rate was signifi-
cantly higher than the actual response rate (P=0.03). 
In conclusion, this pilot study with moderate dosages of a-IFN suggests that the HBeAg 
seroconversion rate after repeated a-IFN treatment is low for previous nonresponders and 
probably is not related to important clinical characteristics that influence the response to 
initial a-IFN treatment. A large controlled ttial with higher doses of a-IFN is desirable to 
further evaluate the benefits of retreatment. 
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Introduction 
In chronic hepatitis B virus (HBV) infections, termination of the viral replicating phase, as 
indicated by HBeAg seroconversion, is accompanied by pronounced clinical, biochemical 
and histological regression of liver disease activity (1,2). Alpha-interferon (IFN) therapy 
usually results in HBeAg seroconversion in 30-40% of the patients (3,4). This fmding 
implies that a-IFN treatment is not successful in more than half of the cases and that these 
patients are left with persisting disease activity. The best therapeutic approach for these 
patients is still not !mown. 
From various reports it appears that patient characteristics, such as immunocompetence 
and the degree of both inflammatory activity and viral replication, can influence the 
response to a-IFN therapy (3,5). 
To determine the effect of repeated courses of a-IFN we studied the results of a-IFN 
retreatment in patients who did not respond with HBeAg seroconversion to previous 
courses of a-IFN. Furthermore, we investigated the predictive value of clinical pretreat-
ment factors for response to a-IFN therapy. 
Patients and Methods 
Twenty courses of a-IFN retreatment were given to 18 chronic hepatitis B patients who 
did not respond to previous therapy. Only patients who had received an initial course of 
lymphoblastoid a-IFN (Wellferon,Wellcome,Beckenham,U.K.) for at least 16 weeks in a 
dosage of more than 20 MU per week were included in the study. The repeated a-IFN 
course started after a therapy-free period of at least 6 months. All patients were seropositi-
ve for HBeAg and HBV-DNA in the 6 months preceding the start of the repeated therapy. 
Liver biopsies were taken within a 3-month period prior to repeated therapy. For the 2 
patients who received two courses of a-IFN retreatment only the last course was analyzed. 
During the repeated course lymphoblastoid a-IFN was given subcutaneously for a period 
of 4 months in an increasing daily dose of 1.5 MU (4 weeks), 3 MU (8 weeks) and 5 MU 
(4 weeks). Follow-up ended 52 weeks after the start of this course of therapy. 
Treatment effects were monitored by quantitative measurement of HBV -DNA, HBeAg and 
aspartate aminotransferase (AST) in serum obtained weekly during therapy and monthly in 
the follow-up period. Every 3 months additional biochemical and virological measure-
meats, including the prothrombin time, HBsAg and the levels of alanine aminotransferase, 
albumin and bilirubin, were performed. A response was defmed as the occurrence of 
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HBeAg seroconversion and clearance of serum HBV-DNA. 
HBsAg and HBeAg were assessed by means of commercial radioimmunoassay kits 
(Abbott, lli., USA). For quantification of HBeAg a PIN ratio (counts of patient sam-
ple/counts of negative control sample) was determined for each patient using a fixed 
serum dilution. HBeAg seroconversion was defmed as a PIN ratio below 2.1 for undiluted 
serum from 2 successive blood samples. HBV-DNA was measured by a liquid hybridizati-
on assay using an iodine-125 probe (Abbott, lli., USA). 
To analyze whether the results were related to patient characteristics of value for predic-
ting the response to initial tteatment, a predicted response rate - based on pretreatment 
AST level, anti-HIV status and history of acute hepatitis -was determined for the repeated 
a-IFN courses (5). This prediction was compared to the actual response rate for the repea-
ted a-IFN therapy. A positive response was predicted for the following pretreatment 
states: anti-HIV negative, history of acute hepatitis and an AST level above 45 U/1 or 
aoti-HIV negative, no history of acute hepatitis and an AST level above 85 U/1. 
The Fisber exact test was used for statistical analysis. 
Table 1. Patient characteristics a1 the stan of the repealed a-IFN course (n = 18). 
Male/Female 
Age1 (yr) 
Hetero/Homosexual 
Caucasian/Oriental 
Known duration of infection' (months) 
Interval between start of a-IFN therapies' (months) 
CPH/CAH/Cirrhosis/Unknown 
HBV -DNA' (pg/ml) 
AST1~ (U/1) 
History of Acute Hepatitis' 
Anti-HIV positive" 
1: median (range); 
2: response predictive factor 
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15/3 
38 (25-64) 
13/5 
17/1 
60 (24-108) 
21.5 (13-52) 
4/8/511 
109 (5-819) 
45 (19-475) 
2/16 
0/18 
Results 
Patient characteristics at the start of the repeated course are shown in table 1. Histological 
evidence of chtonic hepatitis was found for all patients who underwent a liver biopsy 
(n=17). AST levels were elevated in 16 of the 18 patients. None of the patients were 
seropositive for antibodies to hepatitis C or hepatitis delta virus. One patient was of 
Chinese origin. one Turkish; all the others were West-European caucasians. 
At the end of follow-up 2 of the 18 patients (11 %) had responded to therapy (figure 1). 
The responses occurred at week 10 and 14 of treanuent. Two patients became negative 
only for HBV-DNA, one of them relapsed to HBV-DNA positivity after cessation of 
therapy. All patients remained HBsAg positive. 
Figure 2 shows the median level of HBV-DNA and AST. During therapy the HBV-DNA 
and HBeAg levels decreased by 80% and 31%, respectively. There was more than a 50% 
... 
60 
50 
40 
30 
20 
10 
r----l---,22% 
0 '----'-----
.,.,.k 16 
(end ol therapy) 
11% 
D HBV-DNA negative 
R HBeAg aeroconveralon 
week 52 
Figure 1. Percemage of patients who exhibited clearance of HBV-DNA and HBeAg at the 
end of the repeated <x-IFN course and at the end of follow-up (n=l8). The venical lines 
denote the 95% confidence imerval. 
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Figure 2. Median HBV-DNA and AST levels during trearment and follow-up of the 
repeated a-IFN course (n=l8). 
reduction of the HBV-DNA level in all 18 patients and of the HBeAg level in 5 of the 18. 
The AST level showed only minor fluctuations without evidence of a clear peak that ntight 
be indicative of the immunological response which can terminate the HBV replicating 
phase. Only 2 of the 18 patients - both nonresponders - exhibited a more than 2-fold rise 
in AST levels during a-IFN treatment. 
On the basis of the pretreatment characteristics, a response was predicted for 9 of the 18 
patients (50%); the predicted response rate was significantly higher than the actual 
response rate for a-IFN retreatment (P=0.03). Both responders belonged to the group of 
patients for whom a response was predicted. 
One of the 2 patients who received a total of 3 a-IFN courses exhibited a response in the 
lOth week of the second course. which consisted of interntittenl a-IFN therapy (figure 3). 
However, 12 weeks after the therapy was discontinued he suffered a relapse: both the 
HBeAg and HBV -DNA became positive with a sudden rise in antinotransferase levels. His 
last course of therapy which started 6 months after the relapse was unsuccessful. The AST 
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level for this patient was 3 to 4 times higher at the start of his second course as compared 
to the other - nonresponsive - courses. 
HBV-DNA 
AST 
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• • • • • • • • • 
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6.0 mu 
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• • • • HBeAg 
30 5.0mu 1
"
5 
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3637383940 
Figure 3. HBeAg status and levels of HBV-DNA and AST for a patienJ who received 3 
courses of a.-IFN and exhibited a response and relapse during the second course. 
Discussion 
The effects of a.-IFN retreatment in chronic HBV-infected patients have not yet been 
studied in detail. In this pilot study the HBeAg seroconversion rate for repeated a.-IFN 
treatment of previous nonresponders appears to be low (11%). The type of interferon used 
aod the duration of the successive therapeutic courses were comparable for each patient. 
According to the prediction model described by Brook (5), a response was predicted for 
9/18 (50%) patients. This figure was significantly higher than the actual response rate for 
retreatment. According to the same prediction model. none of the 18 patients were 
expected to respond to the first course of treannent. Thus, there was no difference 
between the actual aod the predicted response rates for initial therapy (figure 4). 
In all patients there was a clear decline in HBV -DNA levels during retreatment, sugges-
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ting the presence of a direct inhibitory effect of a-IFN on HBV replication. However, the 
virus-specific immunological response, which is usually reflected by a rise in inflam-
matory activity (AST) and might be the most prominent effect of a-IFN therapy, appeared 
to be absent in most of the patients. It thus seems important to focus on the immuno-
regulatory properties of a-IFN to unravel the problem of nonresponse. a-IFN leads to an 
increased expression of HLA type I protein on the hepatocyte snrface, thereby facilitating 
recognition and lysis of virus-infected cells by the cellular immune system. This a-IFN-
induced immunological response is accompanied by a rise in serum tumor necrosis factor 
a, interleukin-1~ and the CD4/CD8 lymphocyte ratio; it is unknown, however, whether 
these phenomena themselves exert a specific antiviral action or whether they only coincide 
with other more important steps in the cascade of cytokine activities. Unfortunately, the 
outcome of a-IFN therapy cannot be predicted by the pretreatment CD4/CD8 lymphocyte 
ratio, natural killer cell activity or lymphocyte proliferative response (6,7). 
- Initial treatment 
'!1. response 
80 
60 
50% 
40 
20 
0% 
o~_,._~----
predicted response 
- Repeated treatment 
11% 
0% 
actual response 
Figure 4. The predicted arul actual response rates for the initial arul repeated a-IFN 
course. The vertical lines denote the 95% confidence interval. 
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Other factors that might influence the response rate are the number of cellular IFN recep-
tors and the level of antibodies to C<-IFN. The IFN receptor expression appears to drop 
quickly after C<-IFN treatment is started (8). This inhibitory effect might be compensated 
by an increase in the IFN receptor binding affinity (9). Nevertheless, patients with 
different patterns of response to C<-IFN treatment do not seem to differ in the expression 
of lFN receptors on peripheral blood mononuclear cells. Antibodies to C<-IFN were not 
present in any of the patients in this study (data not shown). The question whether C<-IFN 
antibodies indeed influence the a-IFN response rate is still a subject of debate (10,11). 
Maybe these antibodies play an important role in the low responsiveness of patients from 
oriental areas (12). 
It is unclear whether longer a-IFN retreatment with higher dosages would be more 
effective than the therapeutic regimen used in the present study. Longer courses of therapy 
looks promising for patients who partially respond to a first course of a-IFN (13) and 
might be efficacious for those who previously did not respond to the standard (16 week) 
a-IFN therapy. Combination of antiviral agents is also an option but the results of a-IFN 
combined with acyclovir, adenine arabinoside monophosphate or prednison have been 
disappointing for patients undergoing initial treatment (3,14,15). Regimens combining a-
IFN with ')'-interferon or interleukin-2 are also not superior to a-IFN alone (16,17). 
However from a theoretical viewpoint the combination of different cytokines appears to be 
attractive and this alternative certainly deserves further evaluation (6). Another approach 
for repeated therapy is to follow the patient regularly until the time when the amino-
transferase levels have increased (preferably > 100 U/1) or the HBV-DNA levels are low 
(preferably < 50 pg/ml). Starting retreatment at that moment might result in enhanced 
response rates (18). Nevertheless, in our experience only 2 of the 9 patients with 
promising pretreatment factors responded to a-lFN retreatment. Thus, the predictive value 
of clinical pretreatment factors derived from first a-IFN courses (anti-HIV status, history 
of acute hepatitis and aminotransferase levels) was not confirmed for repeated a-IFN 
therapy in this study. 
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Abstract 
We compared two solution hybridization assays, the Aff!Probe assay (Orion Corporation) 
and the Abbott HBV-DNA assay (Abbott), for quantitative measurement of hepatitis B 
virus (HBV) DNA in serum samples obtained from chronic HBsAg carriers. Forty 
transversally collected (group 1) and 83 serially collected (group 2) serum samples from 
chronic hepatitis B patients were tested with both assays. The serial serum samples were 
obtained from 6 patients who underwent a-interferon therapy with different outcomes 
(nonresponse, HBeAg seroconversion, HBeAg and HBsAg seroconversion). 
In group 1 we found a good correlation (r=0.91; P<0.001) between the HBV-DNA 
results of the two assays. Two samples (5%) were HBV-DNA positive according to the 
Abbott but negative according to the AfflProbe assay; for all other samples the HBV-DNA 
status corresponded. In group 2 the assays gave colinear HBV-DNA results during follow-
up of 5 of the 6 patients (correlation for the total group: r=0.90; P<0.001). Neverthe-
less, in both groups the AfflProbe assay yielded about 5-10 times higher HBV-DNA levels 
than the Abbott HBV-DNA assay (P<O.OOI). These discordant results were most 
probably due to standardization differences of the positive control samples of the two test 
systems. This observation underlines the need for international standardization of HBV-
DNA and uniform reference panels. 
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Introduction 
Advances in hepatitis B virus (HBV) DNA detection methods based on molecular 
hybridization techniques have opened the way for reliable quantification of HBV replicati-
on (1,2,3). As a result HBV-DNA has become an important parameter of the effect of 
antiviral therapy (4). Assays presently used to detect other markers of viral replication, 
such as hepatitis B e antigen (HBeAg) or the expression of hepatitis B core antigen 
(HBcAg) in liver cells, are difficult to quantify and therefore less suitable for treatment 
monitoring. Furthermore, the liok between viral replication and HBeAg has been 
questioned since the discovery of HBV pre-core mutants that replicate without producing 
HBeAg (5). 
HBV-DNA detection by dot-blot hybridization is widely used in research laboratories but 
is not yet applied in routine diagnostic laboratories. A similar problem exists for the 
quantification of HBV-DNA after amplification by polymerase chain reaction (PCR) (6,7). 
Hybridization in solution, which has been found to be suitable for HBV -DNA detection in 
serum, was recently incorporated in commercial test systems. The Abbott HBV-DNA 
assay (Abbott Laboratories, Chicago, lil., USA) which is based on the separation of 
hybrids and free probe by column chromatography, appears to give satisfactory quantitati-
ve results (8,9). Using sera obtained primarily from chrouic hepatitis B patients under-
going a-interferon therapy we compared the HBV-DNA results of this assay with those of 
another solution hybridization assay (AfflProbe assay, Orion Corporation, Helsinki, 
Finland) which depends on affmity-based hybrid collection (10,11) 
Materials and Methods 
Patients and Serum Samples 
Two groups of sera were selected from chrouic hepatitis B surface antigen (HBsAg) 
positive patients: Forty serum samples (group 1) were collected transversally from 36 
patients. These sera were classified on the basis of the HBV-DNA level measured by the 
Abbott HBV-DNA assay as follows: below 1.7 pg/ml (under the cut-off; group 1A), 1.7 
to 50 pg/ml (group 1B), 50 to 100 pg/ml (group 1C) and above 100 pg/ml (group lD). 
Each of these subgroups included 10 sera. All samples were negative for antibodies 
against the human immunodeficiency virus; antibodies against hepatitis C and D virus 
were detected in 1 and 4 of the serum samples, respectively. All sera which tested HBV-
DNA negative in the Abbott HBV -DNA assay were also negative for HBeAg; all other 
sera were HBeAg positive. 
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Eighty-three serum samples (group 2) were collected serially from 6 patients treated with 
a-interferon and followed for a period of 1 year. Sera were obtained every 4 weeks 
during a-interferon therapy and every 4-16 weeks in the period thereafter. All patients 
received 5 mega-units lymphoblastoid a-interferon (Wellferon, Wellcome, Beckenham, 
UK) per day according to the same protocol: a 4-week primer course, 4 weeks without 
therapy and a second a-interferon course lasting 16 weeks (12). All patients were HBeAg 
positive and had elevated serum aspartate antinotransferase levels at the start of therapy. 
None exhibited antibodies against hepatitis C or D virus or against the human immunode-
ficiency virus. Two patients remained HBeAg positive, 2 patients exhibited HBeAg 
seroconversion and 2 patients exhibited both HBeAg and HBsAg seroconversion during 
follow-up. One of the patients who only seroconverted for HBeAg showed HBeAg 
reactivation after cessation of therapy. 
Affinity-based Hybridization Assay (Affi.Probe Assay) 
The AffiProbe assay is based on sandwich hybridization in solution followed by affinity-
based hybrid collection (10,11). Target HBV-DNA is allowed to hybridize with a 35S-
Iabelled detector probe and a biotinylated capmre DNA. The hybrids formed are then 
collected onto an affinity matrix coated with streptavidin, from which they are eluted for 
measurement by scintillation counting. Detectable label is bound to the matrix if the 
correct target is present in the reaction. 
The concentration of the positive control was 1.67 x 109 HBV-DNA molecnles (5840 
pg/ml; cloned double stranded DNA) per ml. The diluent for the test samples was used as 
negative control. Thirty 1'1 of the control samples were tested in duplicate and the mean 
cpm values were used. The cpm values for the negative control and the 1/100, 1/10 and 
1/1 dilutions of the positive control sample (equivalent to 5 x 10', 5 x 106 and 5 x 107 
DNA molecnles, respectively) were plotted logarithmically for construction of the standard 
curve. The cut-off value - if at least 40 cpm and 1.5 times the cpm for the negative 
control - was set as the cpm value for the 11100 dilution of the positive control. The 
manufacmrer allows the use of 50 to 500 1'1 sample volumes; we chose a 100 1'1 sample 
volume which is standard for the Abbott HBV-DNA assay. The detection level for the 
AffiProbe assay using 100 1'1 of sample was 17.2 pg!ml. 
Column-based Solution Hybridization Assay (Abbott HBV-DNA Assay) 
The Abbott HBV-DNA assay was performed according to the instructions of the manufac-
turer (Abbott, Chicago, !11, USA) (8). Briefly, 3 separate reagents were added to 100 1'1 
of serum for solubilization and denaturation of the nucleic acids. A 125I-labelled HBV-
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DNA probe was then added to the samples for overnight hybridization. Free probe was 
separated from the 125I-labelled hybrids by passage over a prepacked column. After elution 
of the hybrids from the column radioactivity was measured in a gamma counter. The 
amount of HBV-DNA, expressed as pg/ml, was calculated according to the following 
formula: 
sample counts - mean negative control counts 
--------------------------------------x103 
mean positive control counts - negative control counts 
The concentration of the positive control was 3 x 107 genomes/ml (103 ± 10 pg/ml; 
native HBV-DNA). The detection level of the assay was 1.7 pg of HBV-DNA per mi. 
Polymerase Chain Reaction 
Serum samples were subjected to HBV-DNA extraction and amplified by means of a 
polymerase chain reaction (PCR) as described previously (13,14). Two oligonucleotide 
primer sets that were specific for the surface and core regions of the HBV-DNA genome 
were used. Absence of HBV -DNA for both primer sets was considered a negative result. 
Serological Assays 
HBsAg and HBeAg were measured by solid pbase radioinnnunoassays (Abbott, Chicago, 
Ill., USA). Aspartate aminotransferase levels were determined with a sequential multiple 
autoanalyzer (Technicon Instruments Corp., Tarrytown, NY, USA). 
Statistics 
Pearson's correlation coefficient (r) was calculated to assess the correlation between the 
HBV-DNA levels obtained with the two assays. For the serial samples we also calculated 
the correlation coefficient for each individual patient and compared these values to 0, 
using the Wilcoxon signed-rank test. Differences between the HBV-DNA results of the 
two assays or between the AffiProbe/Abbott HBV-DNA ratio's were analyzed with the 
Student's t-test after logarithmic transformation of the HBV-DNA value. HBV-DNA 
results below the cnt-off values of the assays were not quantified and therefore not 
included in the assessment of the correlation or statistical differences. P-values were two-
sided, the significance level was 0. 05. 
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Results 
The HBV-DNA results of the Aff!Probe and Abbott HBV-DNA assay of the samples from 
group 1 (transversal samples) are plotted iu figure 1. Two sera (5%) were HBV-DNA 
negative according to the Aff!Probe assay but positive (2 and 203 pglml) according to the 
Abbott HBV-DNA assay. In all other cases the HBV-DNA status corresponded. Quanti-
tatively, we found a good correlation between the two assays (r = 0.91; P < 0.001). 
However, the AfflProbe assay yielded 2.1 to 17.0 (median 7.1; P < 0.001) times higher 
HBV-DNA values than the Abbott HBV-DNA assay. The difference between the two 
assays was most promiuent for the samples with the higher HBV-DNA levels (table 1). 
The HBV -DNA results found for group 2 (serial samples) are shown iu figure 2. Seven 
samples (8%) tested positive for HBV-DNA (range 2-37 pg/ml) iu the Abbott HBV-DNA 
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Figure L HBV-DNA levels (pglml) in 40 transversally collected serum samples (group 1) 
determined by means of the AffiProbe and Abbott HBV-DNA assays. The samples were 
obtained from chronic hepatitis B patients (HBeAg positive n=IO; HBeAg negative n=30). 
HBV-DNA results below the cut-off level (C. 0.) are not quantified. 
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Table I. Results of the assessment of HBV-DNA with the AffiProbe and Abbott HBV-DNA 
assays in sera obtained from chronic HBV carriers. The sera were classified according to 
the HBV-DNA level obtained with the Abbott HBV-DNA assay: < 1. 7 pglml (below the 
cut-off; group 1A), 1.7 to 50 pg/ml (group 1B), 50 to 100 pglml (group 1C) and > 100 
pg/ml (group 1D). The cut-off value of the AffiProbe assay was 17.2 pglml. Results are 
expressed in median (range). The ratio AffiProbe/Abbott was only assessed for serum 
samples with an HBV-DNA level above the cut-off value. N.A.: not applicable. 
HBV-DNA (pg/ml) 
Group Abbott HBV-DNA AfliProbe Ratio 
Assay Assay Affiprobe/ Abbott 
!A (n=!O) < 1.7 < 17.2 N.A. 
!B (n=!O) 16.5 (2-44) 79.5 ( < 17.2-221) 3.7 (2.1-10.4) ..., 
I 
I 
!C (n=10) 79 (68-94) 668 (198-1200) 8.1 (2.7-14.8) I P=O.O! 
I 
I 
lD (n=!O) 221.5 (123-836) 2275 ( < 17.2-6101) 9.7 (5.1-17.0) _J 
assay and negative in the AffiProbe assay; one sample was HBV-DNA positive (20 pg/ml) 
according to the AffiProbe assay and HBV-DNA negative according to the Abbott HBV-
DNA assay. As for group I we found a good correlation (r = 0.90; P < 0.001) between 
the assays with 7.5 (median value) times higher HBV-DNA values obtained with the 
AffiProbe assay (P < 0.001). When the individual patients were analyzed the HBV-DNA 
values cbanged during follow-up in a linear fashion for 5 of the 6 patients, irrespective of 
the pattern of response to a-interferon therapy (figure 3; r = 0.34-0.96; P = 0.03). Two 
patients cleared HBV -DNA when measured with the PCR technique: one who only 
exhibited HBeAg seroconversion reactivated for HBV-DNA and HBeAg, the other who 
also exhibited HBsAg seroconversion remained HBV-DNA negative. 
Since we consistently observed 5-10 times higher HBV-DNA values with the AffiProbe 
assay compared to the Abbott HBV-DNA assay we tested the HBV-DNA level of the 
positive control (HBV particles in serum) of the Abbott HBV -DNA assay in the AffiProbe 
assay. The Aff!Probe assay yielded a value that was 6.9 (707 pg/ml) times the HBV-DNA 
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Figure 2. HBV-DNA levels (pglml) for 83 serial serum samples (group 2) determined by 
the AffiProbe and Abbott HBV-DNA assays. The samples were obtained from 6 HBeAg-
positive chronic hepatitis B patients who were treated with ex-interferon. HBV-DNA results 
below the cut-off level (C. 0.) are not quantified. 
concentration that was supposedly present in the Abbott HBV-DNA assay control sample. 
The Abbott HBV-DNA assay did not detect the cloned HBV-DNA from the AffiProbe 
control sample. 
Discussion 
In this study the AffiProbe assay for detection of HBV -DNA was evaluated and compared 
with the Abbott HBV-DNA assay. The HBV-DNA values obtained with the two assays 
exhibited a close correlation. for both transversally and longitudinally obtained serum 
samples. Discrepancies in the (qualitative) HBV-DNA status were rare among the 
transversal samples. In the group of serial samples differences in the HBV-DNA status 
were found for two patients. one with unexpectedly large sequential HBV-DNA changes 
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according to the AfflProbe assay, the other suggesting a minor rebound phenomenon 
according to the Abbott HBV-DNA assay only. 
To obtain optimal comparability we used the same sample volume (100 !'I) in each test. 
According to the manufacturers' instructions this resulted in a 1. 7 pg/rnl cut-off level for 
the Abbott HBV-DNA and 17.2 pg/rnl for the AffiProbe assay. Since the HBV-DNA 
values obtained with the AffiProbe assay were generally 5-10 times higher than those of 
the Abbott HBV -DNA assay - a fmding that was also reported by others (G Gerken, 
personal communication) - the difference in cut-off level did not markedly influence the 
sensitivity of the AffiProbe as compared with the Abbott HBV-DNA assay. The divergen-
ce between the HBV-DNA values of the Aff!Probe and Abbott HBV-DNA assay was most 
notable for sera with high HBV -DNA concentrations. 
In practical terms both the AfflProbe and the Abbott HBV-DNA assay appear to be 
suitable for HBV -DNA monitoring of patients undergoing antiviral therapy. Since both 
tests are based on nucleic acid hybridization in solution, they ensure easier handling of 
samples and a faster hybridization rate than solid phase hybridization techniques (3 ,5). In 
addition, the results are given in numerical values which allows unequivocal interpretation 
and circumvents the possible interobserver variation of dot-spot methods. Nevertheless, 
the assays described in this study could be improved by eliminating the radioactive probes 
which require safety precautions and limit the shelf-life of the test kits (15,16). In our 
experience the AfflProbe assay appeared to be more elaborate than the Abbott HBV-DNA 
assay due to the many working steps involved, including ethanol precipitation and 
resuspension of DNA, a step that may introduce an experimental error. For example, loss 
of the HBV -DNA containing pellet after precipitation could potentially lead to false 
negative results. The instructions of the Aff!Probe assay suggest using 50 and 500 !'! of 
serum. In our experience a volume of 100 !'I of serum, as was used in the Abbott HBV-
DNA assay, resulted in satisfactory assessment of HBV -DNA levels in most samples. 
However, for precise quantitative measuremem of low-range HBV-DNA samples and for 
therapeutic endpoint determinations, the use of 500 !"I of serum appears preferable because 
of its lower detection level. 
The question which of the 2 assays gives the closest approximation of the actual HBV-
DNA content of the samples is difficult to answer. Since the Aff!Probe assay uses cloned 
HBV-DNA (circular covalently closed double stranded DNA) as standard which fits in the 
format of that assay but not in that of the Abbott HBV-DNA assay which uses native 
HBV-DNA (partially single stranded DNA), positive control samples could not be exchan-
ged. The result for the Abbott control sample tested in the Affiprobe assay was in 
agreement with the results for the patiem samples in which 5-10 times higher HBV-DNA 
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Figure 3. HBV-DNA levels (pg!ml) found by means of 
the AjjiProbe (a-o) and Abbott HBV-DNA (*----
-*) assays for 6 patients (group 2) undergoing a-
inteiferon therapy. Two patients remained HBeAg 
positive (panel A), 2 patients exhibited HBeAg sera-
conversion (panel B) and 2 patients exhibited both 
HBeAg and HBsAg seroconversion (panel C) during 
follow-up. The cut-off HBV-DNA level was 17.2 pg!ml 
for the AjjiProbe (0-----0) and I. 7 pglml for the Ab-
bott HBV-DNA (*-----*) assay. IFN: a-inteiferon; 
PCR: HBV-DNA measured with polymerase chain 
reaction. F~ 
levels were found in the Aff!Probe compared with the Abbott assay. This observation 
reduces the discordant but consistent differences between the two assay systems to 
standardization differences of the positive control samples. Defining an HBV-DNA 
standard with native DNA may suffer from differences in the relative composition of 
structural forms of the viral DNA between the standard virus preparation and the sera of 
patients. On the other hand, the use of cloned viral HBV-DNA as standard, as was done 
earlier in dot blot hybridization, may be hampered by the fact that cloned HBV-DNA does 
not simulate solubilization and hybridization properties of native HBV-DNA in the assays. 
The differences in the quantitation of HBV -DNA in this study prove that there is a clear 
need for standardization and assessment of a uniform HBV-DNA reference panel. The use 
of complete hepatitis B virion appears to be the most realistic option for these reference 
sera. At present several European centers are trying to achieve this goal in concerted 
action (17). 
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Abstract 
For the monitoring of chronic hepatitis B patients undergoing antiviral therapy, 
measurement of hepatitis B virus (HBV) DNA is widely used in research laboratories but 
is not yet a routine clinical procedure. We investigated whether quantitative measurement 
of HBsAg can be used to monitor viral replication in chronic hepatitis B patients under-
going a-interferon therapy. HBsAg was measured quantitatively in serum samples 
collected serially before and after the HBeAg seroccnversion date from 69 patients with 
HBeAg seroconversion and 17 patients with both HBeAg and HBsAg seroccnversion. 
Serial samples from 39 HBsAg-positive patients without seroconversion (18 HBeAg 
positive, 21 HBeAg negative) served as controls. From 12 other patients on a-interferon 
therapy (nonresponse n=6, HBeAg seroconversion n=3, HBeAg and HBsAg serocon-
version n=3) monthly samples were collected until 6 months after cessation of therapy. 
HBsAg was measured quantitatively with an inununometric assay (Amersharn, UK) and 
compared to the levels of HBV-DNA and HBeAg. In 56/69 (81 %) patients with only 
HBeAg seroconversion, the HBsAg level dropped after HBeAg seroconversion; the 
median HBsAg level was 8.39 !'glml (range 0.01-57.51) before HBeAg seroconversion 
compared to 3.53 !'g/ml (range 0.002-68.66) after seroconversion (P<0.001). No 
siginificant decrease in HBsAg was found for the control group. For the group of 12 
patients treated with a-interferon we found parallel resnlts and a good correlation between 
the HBsAg level and both the HBV-DNA (r=0.76; P<0.001) and the HBeAg (r=0.70; 
P < 0.001) level, irrespective of the response pattern. 
Quantified assessment of HBsAg appears promising as a simple and cheap method for 
monitoring viral replication in chronic hepatitis B. This test deserves to be further 
evaluated and compared with quantitated HBeAg and HBV DNA assays to deterntine its 
usefulness for medical decision-making regarding a-interferon therapy. 
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Introduction 
Chronic hepatitis B is a common liver disease which may progress to cirrhosis with such 
complications as portal hypertension and hepatocellular carcinoma (1,2). With the 
availability of effective antiviral agents for chronic hepatitis B, quantitative monitoring of 
hepatitis B virus (HBV) replication has become an important factor in patient management 
(3,4). The aim of antiviral therapy is to induce a transition from active HBV replication to 
viral latency which is usually accompanied by arrest of disease progression (5,6). To 
monitor HBV replication measurement of HBV-DNA is widely used in research laborato-
ries but not in routine clinical laboratories because of its time-consuming methods and its 
high cost in material and personnel (7,8). There is a need for a simple and cheap assay to 
assess the level of HBV replication. 
Hepatitis B "surface" antigen (HBsAg) was the ftrst hepatitis B-related antigen discovered 
and is by definition present in all chronic hepatitis B patients (9). HBsAg testing is 
therefore part of the routine diagnostic assessments in almost every hospital around the 
world. We investigated the level of HBsAg in patients who exhibited cessation of viral 
replication, as indicated by clearance of HBeAg and HBV-DNA. Furthermore we 
determined whether quantitative measurement of HBsAg can be used as a marker of viral 
replication in patients undergoing a-interferon therapy. 
Patients and Methods 
Patients and Treatment 
HBsAg was assessed quantitatively in sera collected from 4 different groups of chronic 
HBsAg carriers (total of 137 patients): Sixty-nine patients exhibited HBeAg 
seroconversion (group A), 39 after a-interferon therapy (5 MU per day for 4 to 6 months) 
and 30 spontaneously. Seventeen patients exhibited both HBeAg and HBsAg 
seroconversion within 6 months (group B), 8 after a-interferon treatment and 9 
spontaneously. Thirty-nine HBsAg-positive patients (HBeAg positive n=18; HBeAg 
negative n=21) without a-interferon therapy and without HBeAg and/or HBsAg 
seroconversion served as controls (group C). Two serial samples were collected 6 to 12 
months before and after the HBeAg seroconversion date; similarly in the control group 
two sera were collected 12 to 24 months apart. The remaining group (group D) consisted 
of 12 patients who were followed longitudinally during a-interferon therapy with different 
outcomes: nonresponse in 6, HBeAg seroconversion in 3 and HBeAg as well as HBsAg 
seroconversion in 3 patients. a-Interferon was given in a dose of 5 MU daily. in courses 
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of 1 and 4 months duration, separated by one month of rest (10). Serum samples of these 
12 patients were collected every month during therapy and every 1-2 months afterwards 
(follow-up 1 year). In addition to quantitative HBsAg measurement, HBV-DNA and 
HBeAg were assessed quantitatively in the samples from group D. 
All patients receiving a-interferon therapy were HBeAg and HBV-DNA positive at the 
start of therapy. HBeAg seroconversion was always accompanied by clearance of serum 
HBV-DNA. All patients studied were negative for antibodies against the human 
immunodeficiency virus and hepatitis C and D virus. 
Laboratory methods 
HBsAg was detected by an enzyme immunoassay (EIA) employing enhanced luminescence 
(Amerlite HBsAg assay, Amersham, United Kingdom). Serum sample and mouse anti-
HBs monoclonal antibody labeled with peroxidase were incubated in microwells coated 
with a second anti-HBs monoclonal antibody of different specificity. After removal of 
unbound material the peroxidase activity of the conjugate was measured by an enhanced 
luminescence reaction (11). The sensitivity of the assay was approximately 0.3 ng/ml of 
HBsAg (ad and ay). When appropriate, samples were tested undiluted or diluted 1/100 
and 1/400 to remain within the detection range of the assay. HBsAg was quantified using 
a serial dilution curve of a reference sample from the Paul Ehrlich Institute (Langen, 
Germany) containing both the ad and ay (mixture 1:1) subtypes of HBsAg. Results were 
expressed in micrograms of HBsAg per ml of serum. HBV-DNA was measured by a 
liquid-phase hybridization assay using an 1251-labelled HBV-DNA probe (Abbott HBV-
DNA assay, Abbott, Chicago, USA). Free probe was separated from the l2SI-labelled 
hybrids by passage over a prepacked column. The HBV -DNA level was expressed in 
picograms per ml of serum; the cut-off of the assay was I. 7 pg/ml. HBeAg was measured 
by a radioimmunoassay (Abbott HBeAg test, Abbott, Chicago, USA). For quantification 
the PIN ratio (counts patient sample/counts negative control sample) was determined. For 
each patient a flxed serum dilution (1/1, 115, 1125, 11125 or 1/625) was maintained. 
HBeAg seroconversion was defmed as a PiN ratio below 2.1 for undiluted serum. 
Statistics 
Medians were used because the HBsAg results lacked a normal distribution (also after 
logarithmic transformation). The two-sample Wilcoxon rank sum test was used to analyze 
unpaired observations and the Wilcoxon signed rank test to analyze paired observations. 
Spearman's correlation coefficient (r) was calculated to assess the correlation between the 
levels of HBsAg and HBV-DNA or HBeAg. P-values were two-sided, the significance 
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level was 0.05. 
Results 
The levels of HBsAg before and after seroconversion for HBeAg and HBsAg are 
illustrated in table 1. The HBsAg level decreased in 56 of the 69 patients who exhibited 
only HBeAg seroconversion (group A; median decrease of 59%; P<O.OOl). The median 
decrease in HBsAg was 59% for patients with a-interferon-induced HBeAg seroconversion 
and 55% for those with spontaneous HBeAg seroconversion. The difference between the 
HBsAg levels before and after HBeAg seroconversion was significant for both groups. 
The median HBsAg level in the initial samples was higher for the patients who underwent 
both HBeAg and HBsAg seroconversion (group B) - independent of a-interferon therapy -
in comparison to those who only exhibited HBeAg seroconversion (group A); these 
differences were not statistically significant. 
For both the HBeAg-positive and HBeAg-negative control group (group C) we did not 
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Figure 1. HBV-DNA and HBsAg levels in 148 serum samples obtained from 12 chronic 
hepatitis B patients (group D) treated with a-inteiferon. 
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Table 1. Median HBsAg level (range) before and after HBeAg seroconversion or HBeAg and HBsAg seroconversion. 
A 
HBeAg IFN treatment 
seroconversion 
No treatment 
Total 
B 
HBeAg and HBsAg IFN treatment 
seroconversion 
No treatment 
Total 
c 
HBeAg~positive controls 
HBeAg-negative controls : 
* cut-off HBsAg assay: 0.3 ng/ml 
N.A.: not applicable 
n 
39 
30 
69 
8 
9 
17 
18 
21 
HBsAg level (~g/ml) 
month 0 month 12 
8.39 (0.01-57.51) 3.53 (0.002-68.66) 
8.43 (0.02-52.12) 3.63 (0.002-65.99) 
8.39 (0.01-57.51) 3.53 (0.002-68.66) 
32.58 (4.12-42.31) < 0.001' 
12.04 (0.02-61.69) < 0.001' 
13.09 (0.02-61.69) < 0.001' 
25.55 (1.51-75.65) 21.70 (0.03-79.43) 
4.96 (0.13-17.12) 6.01 (0.01-17.30) 
P value 
< 0.001 
0.02 
< 0.001 
N.A. 
N.A. 
N.A. 
0.87 
0.18 
HBeAg (PIN ratio) 
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Figure 2. HBeAg and HBsAg lt!Ve/s in 148 serum samples obtained from 12 chronic 
hepatitis B patients (group D) treated with o:-inteiferon. 
fmd significant differences between the HBsAg level in the initial and follow-up serum 
samples (table 1). The baseline HBsAg level for the 21 HBeAg-negative controls was 
lower compared to the HBsAg results of all other subgroups (P<0.05). 
A total of 148 serum samples were obtained from the 12 patients who were followed 
longitodinally during a-interferon therapy (group D). For this group we found co-linear 
results and a good correlation between the HBsAg level and both the HBV-DNA (r=0.76; 
P<0.001) and the HBeAg (r=0.70; P<O.OOl) level (figure 1 and 2). No difference in 
the correlation coefficients was found between patients with different response patterns 
(nonrespone n=6, HBeAg seroconversion n=3, HBeAg and HBsAg seroconversion n=3; 
figure 3). 
Discussion 
In the present stody we assessed the quantitative HBsAg level in relation to loss of HBV 
replication ·and evaluated the usefulness of HBsAg for monitoring antiviral therapy. As in 
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Figure 3, HBV-DNA and HBsAg levels in 4 chronic hepatitis B patients with a dijfere/11 response to o:-i/1/eljeron therapy. 
previous studies, we found that the transition from HBV replication to viral latency, as 
indicated by HBeAg seroconversion, is accompanied by a significant decrease in the 
HBsAg level (12-14). Other s gene encoded proteins, such as pre-Sl Ag and pre-S2 Ag, 
have also been shown to correlate with the degree of HBV replication (15). 
Patients who underwent HBeAg seroconversion (no HBsAg seroconversion; group A) 
during "-interferon therapy exhibited a similar decrease in HBsAg level as patients who 
seroconverted spontaneously, suggesting that therapy-induced and spontaneous HBeAg 
seroconversion result in comparable reductions of the virus load. Since we included only a 
few patients who did not respond to "-interferon we cannot judge whether HBsAg 
assessment prior to therapy could help to predict the outcome of this treatment. Eight 
patients exhibited both HBeAg and HBsAg seroconversion after "-interferon treatment 
(group B). The initial HBsAg level found for these patients was similar to that for those 
who exhibited only HBeAg seroconversion (group A) during therapy, indicating that the 
amount of HBsAg in serum before therapy is not predictive for the occurrence of HBsAg 
seroconversion after a-interferon therapy. 
For patients who were followed closely during "-interferon therapy (group D) we found a 
good correlation between the HBsAg and the HBeAg or HBV -DNA levels. In most 
patients the HBV-DNA level dropped first, followed by the HBeAg and HBsAg levels. A 
similar sequence was described by Zonlim and Hess in previous studies (4,16). 
Interestingly, we found co-linear results for the HBsAg, HBeAg and HBV-DNA levels, 
irrespective of the response (nonresponse, HBeAg seroconversion, HBeAg and HBsAg 
seroconversion) to therapy. The interval between the start of the decrease in the HBV-
DNA and HBsAg levels was short which suggests that the HBsAg level reflects changes in 
viral replication in a direct way. 
With the availability of effective antiviral agents, quantified parameters of HBV 
replication have become important for patient management and the development of new 
treatment regimens. One of the reasons why HBsAg is as yet rarely quantified in studies 
involving antiviral therapy conld be that the range of this antigen can only be covered by 
using several dilution steps in assays presently available for qualitative measurement. 
Using the HBsAg Amerlite kit we were able to obtain reliable quantification in 3 dilution 
steps. More than 80% of the samples could be measured reliably after a 1!100 dilution 
step. A second possible reason for the lack of interest in measuring the level of HBsAg in 
patients treated with "-interferon could be the obvious fact that HBsAg does not disappear 
completely from serum after cessation of viral replication as detected by HBeAg 
seroconversion. Although the HBsAg level decreased in the majority of our patients who 
exhibited HBeAg seroconversion it remained high in some. Therefore we could not define 
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an HBsAg cut-off level which corresponds to disappearance of HBeAg and which could be 
used as endpoint determination for "-interferon therapy. On the other band, quantitative 
HBsAg assessment could indicate in most cases a sigoificant decrease in viral replication 
during therapy like HBeAg and HBV-DNA measurement. In comparison to quantitative 
assessment of HBeAg and HBV-DNA, HBsAg quantitation is less laborious and cheaper, 
especially when performed by assays designed for quantitative measurement (Amerlite 
assay, Abbott lMX). For the many laboratories which do not have the ability to measure 
HBV-DNA or HBeAg quantitatively, HBsAg measurement might be a good alternative to 
assess cbanges in HBV replication. In addition to HBsAg measurement a simple 
qualitative HBeAg/anti-HBe assay indicating seroconversion is most reliable for endpoint 
determination of "-ioterferon therapy. Further studies should elucidate whether the HBsAg 
level can also be used as a virus marker for patients with hepatitis D or for those who 
carry HBV mutants with a deletion in the pre-core region of the genome which impedes 
HBeAg production (17,18). For these patients, who often have active disease without the 
presence of HBeAg, the effect of treatment is currently monitored by assessment of 
antinotransferase levels. 
In conclusion we found that transition from HBV replication to viral latency, as indicated 
by HBeAg seroconversion, is accompanied by a signifcant decrease in the HBsAg level 
and that the quantified HBsAg level correlates well with the quantified HBeAg and HBV-
DNA levels. Therefore quantitative measurement of HBsAg appears promisiog as a simple 
and cheap method for monitoring HBV replication and deserves further evaluation of its 
usefttlness for medical decision-making regarding "-interferon therapy. 
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Abstract 
As a result of an inquiry among 16 European hospitals, in which 2,490 chronic viral 
hepatitis patients have been treated with a-interferon, we report on 9 patients with 
cirrhosis who exhibited a fatal decompensation of their liver disease during or shortly after 
a-interferon therapy. Seven patients had chronic hepatitis B, 1 chronic hepatitis C and 1 a 
co-infection of hepatitis B and C. Four of the 9 patients had no evidence of decompen-
sated liver disease previously (Child classification A at the start of therapy) and 5 exhibi-
ted signs of decompensation in the past (Child classification A (n= 1), B (n=3) and C 
(n=1) at the start of therapy). The pattern of decompensation during therapy included 
ascites in 9, encephalopathy in 7 and jaundice in 6 patients. The cause of death was liver 
failure in 6 and variceal bleeding in 3 cases. Particularly in patients with previously 
compensated liver disease the relation between the fatal decompensation and the a-
interferon therapy appears highly probable. A mechanism which could explain most of the 
observed deaths in this study is that a-interferon induces an exacerbation of inflammatory 
activity, leading to a fatal destruction of the limited residual capacity of the liver in 
patients with cirrhosis. 
The present study suggests that a-interferon can induce a severe aggravation of the liver 
disease and that it is important to closely monitor patients with cirrhosis undergoing this 
therapy. A very careful attitude with regard to a-interferon is necessary for patients with 
decompensated cirrhosis who should only be treated on a clear indication by experienced 
hepatologists. 
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Introduction 
Currently, alpha-interferon is the most promising therapy for chronic viral hepatitis. A 
sustained response can be obtained in approximately 30% of the patients with chronic 
hepatitis B or C (1,2). Also in patients with cirrhosis a-interferon may hnprove the 
outcome of disease and obviate the need for liver transplantation (3). A response in 
chronic hepatitis B, as defined by loss of viral replication (hepatitis B e antigen serocon-
version), is usually accompanied by a transient rise in antinotransferases (4). This 
inflanunatory exacerbation ensues the risk of a hepatic decompensation in cirrhotic 
patients. We describe 9 patients with viral hepatitis related cirrhosis who died from 
decompensated liver disease during or shortly after a-interferon treatment, and discuss the 
possible contributing role of a-interferon. 
Case report 
A 44-year old male with hepatitis B e antigen positive chronic hepatitis B was started on 5 
megaunits of recombinant a-interferon per day at the Rotterdam University Hospital. His 
liver disease was not detected until 6 months previously when he complained of ankle 
edema and ascites after a long car drive from Morocco to the Netherlands. Liver biopsy 
showed a macronodular cirrhosis with active hepatitis and hepatitis B core antigen expres-
sion in 30% of the hepatocytes; endoscopic exantination showed medium-sized esophageal 
varices. At the start of therapy his liver disease appeared to be compensated, both the 
ascites and edema were undetectable with diuretic therapy. During the first 8 weeks of 
treatment he only complained of chills and a slight fatigue, symptoms that can be 
attributed to the a-interferon therapy. In this period the aspartate antinotransferase level 
doubled while no substantial change was found for the serum hepatitis B virus DNA level 
(figure 1). In the 11th week of treatment the patient complained of jaundice, drowsiness 
and reappearance of the ascites. He was admitted to hospital and the a-interferon therapy 
was discontinued. The aspartate aminotransferase and bilirubin level had risen to 830 U/1 
(normal<30) and 93 p.Illol/1 (normal<14), respectively. The anunonia level was 115 
JLIDOI/1 (normal< 30) and a grade IIb encephalopathy was found on spectral analysis of the 
electroencephalogram (5). He was started on lactnlose and 7 liters of ascitic fluid were 
drained. There were no signs of bacterial peritonitis. No markers of any hepatotrophic 
virus causing a superinfection were detected in serum or liver tissue. During the exacerba-
tion the serum hepatitis B virus DNA level dropped to 11 pg/tnl (cut off 1.7 pg/tnl; 
Genostics, Abbott, USA), however no hepatitis B e antigen seroconversion occurred. 
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Flgure L Level of serum hepatitis B virus DNA (pglml), aspartate aminotransferase (u/1) 
and bilirubin (pmol/1) in a chronic hepatitis B patient (case 5) who exhibited a fatal 
decompensation of liver disease during a-inteiferon therapy. 
After 2 more weeks during which the condition of the patient improved (bilirubin and 
aspartate antinotransferase level decreased) he suddenly developed a variceal hemorrhage 
and died. 
Survey 
To review the frequency and clinical aspects of a-interferon related fatal decompensation 
of liver disease a questionnaire was sent out to 19 European centres with a large experien-
ce in a-interferon therapy for chronic vital hepatitis. Sixteen hospitals from 9 countries 
responded. In these centres a total number of 2,490 chronic viral hepatitis patients bad 
been treated with a-interferon. Only cases in which the patient exhibited an aggravation of 
liver disease with fatal outcome during or within 2 months after discontinuation of a-
interferon were included. Eight more cases from 5 different hospitals were reported. From 
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Table la. Characteristics of previously compensated chronic viral hepatitis patiems who exhibted fatal liver failure associated with a-interferon therapy. 
GROUP A 
age sex type of previous dose/duration type of signs of decomp. last results before death HBeAg cause of 
hepatitis decompensation IFN IFN during IFN AST bilirubin albumin seroconv. death 
(Un) <rmol/1) (g/1) 
Case 1a 62 male B No 5 MU t.i.w. recombinant ascites 244 648 43 Yes liver failure 
12 weeks a-2b jaundice 
encephalopathy 
Case2 41 male B No 3 MU t.i.w. recombinant ascites 302 680 28 N.A. liver failure 
(HBe-mutant) 3 weeks a-2b jaundice 
encephalopathy 
Case3 60 female c No 10 MU t.i.w. recombinant ascites 76 410 28 N.A. liver failure 
11 weeks a-2b jaundice 
encephalopathy 
Case4 62 male B No 5 MU daily recombinant ascites 394 226 26 No variceal bleed 
8 weeks a-2b jaundice 
(after steroid 
withdrawal) 
a: reference nr 13. 
N.A.: not applicable; IFN: a-interferon; HBeAg: hepatitis Be antigen; AST: aspartate aminotransferase 
Table lb. Characteristics of previously decompensated chronic viral hepatitis patients who exhibted fatalli~·er failure associated with o:-inteiferon therapy. 
GROUPB 
age sex type of previous dose/duration type of signs of decamp. last results before death HBeAg cause of 
hepatitis decompensation IFN IFN during IFN AST bilirubin albumin seroconv. death 
(U/1) (pmol/1) (g/1) 
Case 5a 44 male B Yes 5 MU daily recombinant ascites 79 88 27 No variceal bleed 
(ascites) II weeks o:-2a jaundice 
(edema) encephalopathy 
Case 6b 44 male Band C Yes 3 MU t.i.w_ lymphoblastoid ascites 289 272 28 N.A. liver failure 
(ascites) 10 weeks jaundice H-R syndr. 
(jaundice) encephalopathy peritonitis 
Case7 70 male B Yes 2 MU t.i.w. recombinant ascites 9 III 34 Yes liver failure 
(ascites) 24 weeks o:-2b encephalopathy 
(variceal bleed) 
(encephalopathy) 
Case Sb 36 male B Yes 2 MU t.i.w. recombinant ascites 16 52 27 Yes variceal bleed 
(ascites) 16 weeks o:-2b peritonitis 
Case 9b 53 male B Yes 2 MU t.i.w. recombinant ascites 500 171 29 No liver failure 
(ascites) 3 weeks o:-2b jaundice 
(HCC) encephalopathy 
a: presented above 
b: patients on waiting list for liver transplantation 
N.A.: not applicable; HCC: hepatocellular carcinoma; H-R syndr.: hepato-renal syndrome; IFN:o:-interferon; HBeAg: hepatitis Be antigen; AST: aspartate aminotransferse 
the total of 9 patients 4 had no evidence of decompensated liver disease (presence of 
ascites, jaundice, encephalopathy or variceal bleeding) before a-interferon therapy was 
started (group A; table 1a) and 5 patients had signs of decompensated liver disease in the 
past (group B; table 1b). From group B, I patient (case 5) appeared to be recompensated 
at the start of treatment while 3 other patients (case 6, 8 and 9) were on the waiting list 
for hepatic transplantation. Case 9 was the only patient with evidence for hepatocellular 
carcinoma. According to the Child-Pugh criteria (6) case 1-5 had class A, case 6, 8 and 9 
class B, and case 7 class C cirrhosis at the start of the a-interferon therapy. 
At the time of death the median age was 53 years. Seven patients had chronic hepatitis B 
of whom 1 (case 2) carried a mutant type of virus with a deletion in the pre-core region of 
the genome which impedes hepatitis B e antigen production (7). One patient had chronic 
hepatitis C and one had a co-infection of chronic hepatitis B (hepatitis B e antigen 
negative) and C. No serum markers that indicate a viral superimposed infection of the 
liver appeared during the period of decompensation in any of the patients. Furthermore 
none had been exposed to hepatotoxic drugs or other possible causes of liver injury. 
Pretreatment histologic examination showed chronic active hepatitis with cirrhosis in all 
cases. The weekly dosage of a-interferon in group A ranged from 9 to 35 MU; in group 
B, 1 patient received a dose of 35 MU/week and 3 less than 10 MU/week. In 7 of the 9 
patients a-interferon was administered thrice weekly. Three of the 6 hepatitis B e antigen 
positive hepatitis B patients exhibited an hepatitis B e antigen seroconversion during 
therapy. The hepatitis C and the hepatitis B mutant infected patients (case 2, 3 and 6) did 
not respond to the a-interferon therapy with normalization of antinotransferase values. The 
clinical complications occurred within the first 3 months of therapy in 7 of the 9 patients. 
In the other 2 patients (case 7 and 8) the scheduled a-interferon course was completed 
with clearance of hepatitis B virus DNA but clinical deterioration developed 2 and 8 
weeks after discontinuation of treatment. The following signs of decompensation were 
present after start of therapy: ascites in 9 patients (previously present in 5), encephalopa-
thy in 7 (previously present in 1) and jaundice in 6 (previously present in 1). Spontaneous 
bacterial peritonitis was found in 2 patients (case 6 and 8; previously present in 1). The 
reported eventual cause of death was liver failure in 6 and hypovolemic shock due to 
variceal bleeding in 3 patients. 
Discussion 
We describe 9 chronic viral hepatitis patients who underwent a-interferon therapy with 
fatal outcome. All patients had cirrhosis and 5 of the 9 had signs of decompensated liver 
99 
clisease previously. It must be empbasized that the patients described were selected from a 
large population treated with <>-interferon. Nevertheless these cases suggest that <>-
interferon treatment can induce a dangerous aggravation of the liver disease and that a 
cautious attimde is warranted for treatment of cirrhotic patients. 
Spontaneous exacerbations of chronic viral hepatitis have been reported to cause severe 
hepatic injury that may result in fatal liver failure (8,9,10). Withdrawal of intmunosup-
pressive or cytotoxic therapy can induce similar complications in patients with chronic 
vital hepatitis (11,12). A first example of fatal exacerbation induced by <>-interferon 
therapy, was recently reported by Marcellin eta!. (13; case 1 of this smdy). 
The relation between liver failure and <>-interferon appeared probable in the patients who 
decompensated during therapy and never bad an episode of decompensation before the 
start of treatment (group A). In case 4 the withdrawal of prednison could have been an 
additional impems for the occurence of the fatal exacerbation. The death of the 4 patients 
who already exhibited signs of decompensated liver disease at the start of treatment (case 
6-9 from group B) might have been secondary to a spontaneous progression of the disease 
and can thus not unequivocally be linked to the <>-interferon therapy. 
In the literamre several explanations can be found for an association between <>-interferon 
and fatal liver injury. In chronic hepatitis B <>-interferon facilitates lysis of virus-infected 
cells by the cellular intmune system which leads to an increase of inflammatory activity 
that could be lethal in a liver with limited residna! capacity (4,9,14). A second possibility 
may be that after clearance of hepatitis B e antigen, whether or not <>-interferon induced, 
coexisting precore mutant hepatitis B viruses are selected (15). These mutants have been 
implicated in fatal exacerbations (16,17). Other recently postulated reasons for liver 
failure secondary to <>-interferon therapy are a direct hepatocellular toxic effect of <>-
interferon and <>-interferon induced autointmune-mediated chronic active hepatitis (18,19). 
In our smdy none of the patients bad evidence of autointmune chronic active hepatitis 
during <>-interferon treatment. 
The clinical pattern of deterioration in our patients mostly involved appearance of ascites, 
jaundice and encephalopathy that progressed even after <>-interferon therapy was stopped. 
A relative late discontinuation of therapy in some of the patients could be mentioned as 
the reason for the nnfavourable outcome. In any case it is clear that careful monitoring of 
cirrhotic patients who develop signs of decompensation under <>-interferon therapy is 
essential. 
Despite the serious adverse effects that can result from <>-interferon in decompensated 
cirrhosis it is - in our opinion - justified to keep a-interferon in consideration as a therapy 
for these patients. Firstly, because a response with transition to viral latency can lead to a 
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marked regression of liver disease and probably prolonged survival (3,20). Secondly, for 
those cases in which liver transplantation remains the only option, transition to viral 
latency reduces the risk of reinfection of the graft (21). It is important, however, that the 
a-interferon therapy in decompensated patients is monitored closely by an experienced 
hepatologist, preferably in a centre with a liver transplantation program. Since 5 of the 9 
patients described received an a-interferon dose under 10 MU per week, a-interferon 
related fatal decompensation is not restricted to high dose courses. Nonetheless, from a 
practical viewpoint it seems prudent to start with a low dose of a-interferon and carefully 
adjust the dose to the clinical, biochemical and virological condition of the patient. If 
severe decompensation occurs, possibilities to alter the course of the disease are early 
discontinuation of a-interferon treatment and in case of severe inflammatory activity a 
corticosteroid rescue course (22). 
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Introduction 
The predominant neuropsychiatric side effects associated with a-interferon (IFN) treatment 
for chronic vital hepatitis are lethargy, lack of concentration, depression, emotional 
lability and confusion (1). We observed generalized seizures during low dose lymphoblas-
toid a-IFN treatment in 3 patients with HBeAg-positive chronic hepatitis B. Neither of the 
patients had a histoty of neurologic disease and we propose that seizures should be added 
to the list of neurotoxic effects of IFN treatment for patients with chronic vital hepatitis. 
Case Reports 
Case I 
A 24-year-old homosexual man with asymptomatic HIV -positive (CDC II) chronic 
hepatitis B, participating in a trial which evaluated combination therapy of a-IFN and 
retrovir, was started on 1.5 MU a-IFN daily; the dosage was increased to 3 MU after 4 
weeks. After 10 weeks of treatment he had a generalized seizure, lasting 5 minutes. After 
recovety neurologic examination, cerebral CT -scan and analysis of cerebrospinal flnid 
were normal. Neuropsychological assessment revealed no signs of HIV -encephalopathy. 
Electroencephalogram showed a diffuse slow wave activity without epileptiform dismrban-
ces. He was started on phenytoin. IFN was continued because no clear relation between 
the seizure and IFN treatment was suspected. Six weeks later he had a second generalized 
seizure, 4 days after discontinuation of phenytoin therapy. He was given carbamazepin; 
the IFN course was completed a few days later. No neurologic sequelae have developed 
until now, 7 months later. 
Case 2 
A 49-year-old man with chronic hepatitis B entered a study of prolonged intermittent IFN 
treatment. He started with 5 MU of a-IFN daily. Four days after the first IFN-course of 4 
weeks he had a generalized seizure. Neurologic examination, electroencephalogram and 
cerebral CT-scan, performed a few days later were normal. He was given diazeparo. IFN 
was reinstituted 4 weeks later and in the third week of this course the patient again 
experienced a generalized seizure. He was started on carbamazepin; IFN was tapered to 
1.25 MU daily and discontinoed 17 weeks later. No seizures or other neurological 
problems have occured until now, 1 year later. 
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Case 3 
A 28-year-old man suffering from chronic renal failure due to hepatitis B related mem-
branoproliferative glomerulonephritis was treated with 3 MU of a-IFN thrice weekly. 
After 2 weeks of IFN treatment he developed a Moraxella peritonitis secondary to 
peritoneal dialysis. He was treated with gentamycin and rifampicin; IFN was continued. 
One week later he had a generalized seizure, lasting 10 minutes. The patient was afebrile 
and signs of peritonitis or meningitis were absent. There was no evidence of hypertensive 
encephalopathy. Diazepam was given; IFN was discontinued. The next day neurologic 
examination, electroencephalogram and cerebral CT -scan were normal; lumbar puncture 
was not performed in view of his normal temperature and rapid recovery. The patient was 
discharged from the hospital elsewhere, 5 days later. No further seizures have been 
observed until now, 8 months later. 
Discussion 
The 3 patients described had seizures which appeared to be related to IFN treatment. 
Apart from the electroencephalographic fmdings in the first patient which could have been 
induced by IFN (2), neurologic investigations were normal and at follow-up no signs or 
symptoms of a cerebral disorder have developed. Seizures have not been reponed 
previously as a side effect of IFN treatment in chronic viral hepatitis. In cancer patients, 
receiving high doses (10-30 MU/m2) of recombinant a-a-IFN, seizures were occasionally 
documented (3,4). Unlike these studies, we used low doses of lymphoblastoid a-IFN and 
the seizures we observed were not accompanied by other neuropsychiatric symptoms. 
The mechanism by which IFN can induce seizures remains unclear. Passage of IFN 
through the blood-brain barrier was reponed in animals (5), however, in humans IFN 
does hardly cross the blood-brain barrier and no correlations between neurotoxicity and 
IFN levels in cerebrospinal fluid could be made. In vitro, !FN is known to enhance the 
excitability of neurons (6). IFN is also known to stimulate endorphin-like activity 
suggesting that interference of IFN with the neuroendocrinic system is possible (7). Thus 
it is questionable whether IFN itself or other induced substances are responsible for the 
neurotoxic effects. 
Now that IFN will be used more extensively in chronic viral hepatitis, it is imponant to 
warn physicians that even low doses of IFN may induce seizures, irrespective of the 
presence of other signs of neurotoxicity. In our experience, combination of adequate 
anticonvulsive medication during continued !FN treatment can be succesful in preventing 
fUrther seizures. 
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Abstract 
We report on 2 attempted suicides and 1 completed suicide during or shortly after alpha-
interferon (IFN) therapy for chronic viral hepatitis. While on therapy all 3 patients 
developed a psychiatric disorder leading to their suicidal behaviour. In a survey among 
flfteen European hospitals 3 cases of attempted and 2 of completed suicide during a-IFN 
therapy for chronic viral hepatitis, were additionally reported. None of the patients had a 
psychiatric history. a-IFN is known to lead to neuropsychiatric symptoms and our 
observations strongly suggest that these mental disorders conld lead to suicidal behaviour. 
Therefore it is important that physicians, patients and their family are informed about the 
potential risk of the emotional and psychiatric disturbances that can occur during a-IFN 
therapy. 
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Introduction 
Alpha-interferon (IFN) has become the major therapeutic modality for chronic viral 
hepatitis. The spectrum of side effects is one of the main drawbacks of this treatment (1). 
Neuropsychiatric toxicity, including cognitive dysfunction, irritability, change in 
personality and emotional lability, give rise to predominantly interpersonal problems, 
discontinuation of work and domestic discord (2,3). Other more serious IFN-induced signs 
of neurotoxicity include delirium, depression and seizures (2-4). These complications are 
thought to be reversible with dose reduction or cessation of therapy. We report on 3 
patients who attempted to commit suicide during or innnediately after treatment with a-
IFN for chronic viral hepatitis. 
Patients 
Patient I was a 49-year-old marketing manager, married and father of three children. He 
had cirrhosis due to chronic hepatitis B with fatigue as major symptom. He had no 
psychiatric history. Serum HBeAg and HBV-DNA were positive and he was treated with 
5 million units lymphoblastoid a-IFN daily. During the first months of therapy he 
complained of anorexia, extreme fatigue and depressive feelings, symptoms that could be 
attributed to a-IFN therapy. Just before cessation (week 12) of the succesful (HBeAg 
seroconversion) a-IFN course his behaviour changed completely. He was noted to be 
overactive, irritable and aggressive. He did not sleep anymore and thought he had 
contracted AIDS. One week later, a compulsary admission to the Psychiatry Department 
was necessary because of suicidal ideation and violent behaviour against his wife. Mental 
status exantination elicited a manic psychosis characterized by agitation, dysphoria and 
persecutory delusions. There were no gross cognitive dysfunctions. One day after 
admission he attempted to swallow a dishwashing brush to deliberately lacerate his 
esophageal varices. Because of this suicidal behaviour and because of aggressive outburst 
towards staff personnel he had to be isolated. He was treated with 5-l 0 mg haloperidol 
daily, recovered completely and could be discharged from hospital within 4 weeks. Until 
now, three years later, he has been without any psychiatric symptoms. 
Patient 2 was a 40-year-old housewife, married and mother of three children. She had 
contracted hepatitis C two years earlier, after receiving blood transfusions during a partial 
hepatectomy after a motorbike accident. Since that time she had suffered severe fatigue. 
She had a history of depressive feelings which occurred as a result of marital problems at 
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the age of 36 years, but she hadn't been in psychiatric treatment. Her aminotransferase 
values were about 5 thnes the upper limit of normal; on liver biopsy she had chronic 
active hepatitis without evidence of cirrhosis. For the chronic hepatitis C infection (serum 
anti-HCV and HCV-RNA positive) she received 6 million units recombinant a-IFN thrice 
weekly. During therapy she became increasingly withdrawn and depressed despite the fact 
that she responded to therapy with normalisation of aminotransferase values. Furthermore, 
she was very disappointed and angry that she could not get enough domestic help to 
relieve her from her daily household work. After 14 weeks of therapy she attempted 
silicide by taking an overdose of diazepam (40-60 mg). She was admitted to hospital and 
a-IFN was discontinued immediately. On admission she was somnolent but not 
disoriented. One day later she -became agitated and insisted on going home. On mental 
status examinstion she exhibited no severe psychopathology, particularly no snicidal 
ideation and she was therefore discharged from the hospital. Subsequently she entered 
psychotherapy and her emotional problems disappeared. 
Patiem 3 was a 62-year-old chronic hepatitis B patient, married and father of two 
children. He had retired from his job as autopsy assistent 1 year before. At this job he had 
been infected with the hepatitis B virus 2.5 years previously. He had no psychiatric 
history. He was serum HBeAg and HBV-DNA positive, and had a mild chronic active 
hepatitis on histologic examinstion. He received 5 million units recombinant a-IFN daily 
for 4 and 16 weeks, separated by a 4-week interval without therapy. At the start of 
therapy he had no complaints. During treatment he complained of fatigue, myalgia, hair 
loss and lack of concentration. These side-effects of a-IFN did not seem to progress 
during the course of therapy. After 19 weeks of treatment he unexpectedly committed 
silicide by jumping before a train. When we - together with his family - retrospectively 
analysed his treatment course, it appeared that about 1 week before his death he had lost 
all interest for his usnal daily activities and had become increasingly apathetic, withdrawn 
and reticent, symptoms suggestive of a depression. He had not overtly expressed snicidal 
thoughts. Nevertheless, his family was convinced that the suicide was related to the mental 
condition induced by a-IFN treatment. 
Discussion 
These 3 patients who became suicidal during or directly after a-IFN therapy were part of 
215 patients with chronic viral hepatitis who have been treated with a-IFN (in courses of 
3 to 6 months duration) at our department since 1985. At the start of a-IFN therapy all 3 
114 
patients lived a relatively normal life and did not have apparent psychiatric problems or a 
psychiatric history. Furthermore, they had no history of alcohol or drug abuse, were anti-
HIV negative and had compensated liver disease with a good short-term prognosis. During 
a-IFN therapy they developed various mental disorders, in particular affective syndromes 
(emotional lability, apathy, depression and mania), that resulted in suicide attempts. The 2 
patients who survived exhibited a complete psychiatric recovery after discontinuation of a-
IFN. 
To obtain more information on the frequency of this serious complication during a-IFN 
therapy we sent out a questionnaire to 19 European centres with large experience in a-
IFN treatment of chronic viral hepatitis (participants of the European community 
sponsored concerted action on viral hepatitis: EUROHEP (5)). We asked about suicide 
attempts during - or within one month of discontinuation of - a-IFN therapy for chronic 
viral hepatitis. Fifteen hospitals from 10 couotries responded. Among a total of 2,575 
patients 2 completed and 3 attempted suicides were reported. One patient had chronic 
hepatitis B, 2 hepatitis C and 2 hepatitis D. Four of the 5 patients received at least 15 
million units a-IFN per week (range 9-26 million units). The duration of therapy varied 
from 1.5 to 12 months (median 6 months). None of the 5 patients had decompensated 
liver disease and although 3 of the 5 contracted hepatitis by intravenous drug abuse none 
had an apparent psychiatric history and none was anti-HIV positive. Previously, Renault et 
a!. described 2 a-IFN-treated patients with delirium who had developed suicidal ideation; 
one of them injected a-IFN intravenously in an attempt to commit suicide (3). 
Since suicide appears to be an uncommon event during treatment with a-IFN, one might 
question whether this complication is indeed associated with a-IFN therapy. We could not 
fmd reports on the incidence of suicide attempts for untreated patients with chronic viral 
hepatitis. The combined incidence of suicide and suicide attempts over a period of 6 
months in the general Dutch population, matched for age and sex to patients described in 
this paper is estimated to be 0.2- 0.6%o (6,7). The observed incidence of suicide attempts 
for our population treated with a-IFN was 13.9%o. The fact that none of our patients had 
serious psychiatric problems prior to therapy, that suicide has also been encoutered among 
a-IFN-treated patients in other hepatology clinics arouod the world and that several mental 
disorders (depression, psychosis and delirium) which could lead to suicidal behaviour are 
acknowledged as side effects of a-IFN therapy (2,3), argue in favor of a relation between 
suicide and a-IFN therapy. 
The exact role of IFN in the origin of the wide range of organic mental disorders is as yet 
uoknown. Although passage of IFN through the blood-brain barrier is limited, psychiatric 
symptoms and EEG abuormalities during IFN therapy have been described in detail 
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(2,3,8). IFN or one of its metabolites could be directly neurotoxic but may also induce 
other substances which interfere with neuronal excitation or neuroendocrine regulation 
(9,10). 
Although we cannot prove directly that c<-IFN induces psychiatric disturbances which lead 
to suicidal behaviour, this complication is so important and dangerous that physicians 
should be aware of the potential risk. Since it is difficult to predict which of the patients 
who exhibit common and reversible side-effects such as fatigue and mood changes are at 
risk of becoming suicidal, both the patient and the family should be informed to recognize 
signs of cognitive dysfunction, psychosis, affective disturbances and suicidality. If these 
signs occur immediate discontinuation of a-IFN therapy and psychiatric treatment are 
indicated, in which case the prognosis is good (3). Furthermore, physicians should be 
reluctant to start patients with a psychiatric history on an a-IFN treatment programme 
without psychiatric consultation beforehand. 
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Introduction 
Chronic hepatitis B is a disease which can lead to cirrhOsis and serious complications such 
as portal hypertension, hepatic failure and hepatocellular carcinoma (1,2,3). For many 
years chronic HBV infections, like other forms of hepatitis, were classified according to 
the histologic degtee of inflammatory activity as chronic persistent or chronic active 
hepatitis (4). Since patients can move from one category to the other and progtession to 
cirrhosis is seen both for patients with chronic persistent and chronic active hepatitis, the 
prognostic value of this classification is presumably low (5,6). Symptoms during chronic 
HBV infections are also unreliable indicators of prognosis since many patients do not have 
any symptoms other than fatigue until the moment they exhibit decompensated liver 
disease. In addition to the results of the liver biopsy, classification of chronic hepatitis B 
should include information on the serum aminotransferase level and markers of viral 
replication (7,8). The latter two parameters are important for assessment of the prognosis 
and pivotal for determination of the necessity and the monitoring of antiviral therapy 
(table 1) (9,10). 
Table 1. Indications for a-inteiferon (lFN) therapy for chronic hepatitis B patients. 
HBeAg HBV-DNA' 
positive positive 
positive positive 
negative positive 
negative negative 
negative negative 
Aminotransferase 
elevated 
normal 
elevated 
elevated 
normal 
IFN 
yes 
no 
yes 
yes 
no 
yes 
no 
* detected with conventional hybridization techniques 
Remarks 
active chronic HBV infection 
monitor for rise in aminotransf. 
if biopsy shows active hepatitis 
if patient's wish 
pre-core mutant 
exclude other liver disease 
if HDV or HCV positive 
Until recently no effective therapy was available for chronic hepatitis B. Although 
corticosteroid therapy can temporarily reduce the inflammatory activity, HBV replication 
usually increases resulting in a detrimental rather than a beneficial effect in the long run 
(11,12). Longitudinal studies on the natural history of chronic HBV infection have shown 
that active viral replication, indicated by serum positivity for HBeAg and HBV-DNA, is 
associated with continuing inflammatory activity and with deterioration of liver disease. 
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Termination of viral replication with HBeAg and HBV -DNA clearance (HBeAg serocon-
version) is usually accompanied by clinical, biochemical and histological remission of 
liver disease activity, and presumably with a better quality of life (13,14). "-IFN can 
induce HBeAg seroconversion in 30 to 40 percent of the patients with chronic hepatitis B 
(15-19). In more than 85% of the cases this response is sustained and more than half of 
the patients become HBsAg negative after long-term follow-up (20). Until now it has not 
been clear whether successful "-IFN therapy reduces the risk for hepatocellular carcino-
ma. 
Modification of the Alpha-Interferon Treatment Schedule 
Standard Treatmen1 
In randomized controlled trials both recombinant and human lymphoblastoid "-IFN have 
been shown to be effective in inducing HBeAg seroconversion in chronic hepatitis B 
patients. Many studies on "-IFN treatment in HBV infections, however, are characterized 
by a considerable heterogeneity in patient population and response rate, contain few 
patients and should therefore be interpreted with caution. Perrillo et a!. (15) reported on a 
large randomized controlled trial of recombinant "-IFN treatment: HBeAg seroconversion 
with histologic improvement was achieved in 38% of the patients who received the 
standard treatment of 5 mega U "-interferon daily for 16 weeks compared to 7% of the 
untreated controls. In the USA and in northwestern Europe the standard duration of "-IFN 
therapy is now considered to be 12 to 16 weeks. The most effective dosage of "-IFN for 
chronic hepatitis B is probably 30 MU per week. Regimens with "-IFN dosages under 15 
MU per week have been shown to lack efficacy while doses above 30 MU weekly are too 
toxic for the vast majority of patients (15). There does not appear to be a difference in 
response rate berween daily dosages and a schedule of 3 administrations per week. 
Prolonged Treatmem 
In several trials from southern Europe "-IFN therapy was given for approximately 24 
weeks (19,21). One of these studies suggests but does not prove an additional effect of 
prolonged treatment schedules. In the UK a comparison berween 12 and 24 weeks of 
lymphoblastoid "-IFN treatment could not demonstrate a beneficial effect of the prolonged 
course (22). The results of this study were, however, markedly influenced by a lack of 
compliance (8 of the 20 patients withdrew from the longer course) mainly due to side-
effects of "-IFN. Results of a pilot study performed in our institute suggest that extending 
"-IFN treatment for up to 32 weeks might eultance the HBeAg seroconversion and HBsAg 
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seroconversion rates (23). Interestingly, none of the patients in this study had to disconti-
nue a-IFN therapy because of intolerance. On the grounds of these results a group of 
European hospitals (Eurohep; 24) initiated a large randomized trial to evaluate whether 
prolongation of a-IFN therapy for chronic hepatitis B is effective in enhancing the rate of 
HBeAg seroconversion in patients who did not respond to standard a-IFN treatment of 16 
weeks duration. 
Intermittent Treatment 
Intermittent therapy is a rather new approach to increase the response rate for a-IFN 
treatment (23). We conducted a pilot Study consisting of a one-month printing course of 
a-IFN, one month of rest and a second course lasting 4 months. The rationale for the 
initial month of therapy was to decrease viral replication and induce a short immunologic 
rebound before the start of the second long-term course, thereby enhancing the possibility 
of successful therapy. Forty-eight percent of these patients exhibited HBeAg serocon-
version. The level of HBV replication, as monitored by quantitative HBV-DNA and 
HBeAg assessment at the start of the second course, was significantly lower than at 
baseline. Furthermore we observed a double flare of the median aminotransferase values, 
indicating that both courses could have induced a response in some of the patients. In our 
opinion these interesting results justify evaluation of intermittent a-IFN therapy in a 
controlled setting. 
Combination Treatment with Alpha-Interferon 
Alpha-lnteiferon and other Immwzemodulating Agents 
A withdrawal course of corticosteroids before a-IFN therapy may combine enhanced 
immunity with suppression of HBV replication. Several controlled trials which evaluated 
the benefit of pretreatment with prednisone (tapered from 45-60 to 15-20 mg per day in 6 
weeks followed by 30-35 MU a-IFN per week for 16 weeks) did not show an additional 
effect of the priming steroid course (15,25,26). Nevertheless, in two trials the HBeAg 
seroconversion rate of the prednisone-a-IFN schedule was markedly higher for the 
subgroup of patients with low aminotransferase levels at baseline. This fmding suggests 
that patients with mild inflammation may benefit from this combination therapy. The 
benefit of combining a-IFN with another immunomodifying agent, levarnisol, is questiona-
ble as a recent study has demonstrated that this combination resulted in a lower response 
rate than a-IFN monotherapy (27). Simultaneous administration of a-IFN with other 
cytokines such as y-interferon or inter!eukin-2 appears to be an attractive option since 
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expression of not only HLA type I but also HLA type II antigens on the hepatocyte 
membrane is stimulated (28). This could lead to an additional impetus for the attack of 
virus-infected hepatocytes by the cellular immune system. However, the results of several 
studies of these combination therapies have so far been disappointing (29,30). 
Alpha-Interferon and Nucleoside Analogues 
In addition to a-IFN, which exerts its antiviral effect primarily by stimulation of cytotoxic 
T cells and inhibition of HBV protein synthesis, nucleoside analogues interfere at a diffe-
rent site in the HBV replication cycle inhibiting HBV DNA polymerase, a crucial enzyme 
for viral DNA synthesis. ARA-AMP, acyclovir and zidovudine are at this moment the 
most extensively investigated agents in HBV infected humans. Garcia and colleagues 
investigated the alternating administration of ARA-AMP and a-IFN in comparison to 
ARA-AMP and placebo (31). No effect of ARA-AMP alone or the combination conld be 
demonstrated. About 25% of the patients receiving ARA-AMP suffered from painful 
paresthesia necessitating dose reduction. The combination of a-IFN with other nucleoside 
analogues like acyclovir, descylovir or zidovudine was extensively studied in our institute. 
As a result of the positive fmdings of preliminary studies on the combination of a-IFN 
with acyclovir derivatives (32,33), we initiated a large randomized controlled trial 
comparing patients on combined a-IFN (5 MU daily for 16 weeks) and acyclovir (2 g 
daily iv for 4 weeks) therapy with untreated controls (34). Only 25% of the treated 
patients responded with HBeAg seroconversion as opposed to 14% of the controls. Simi-
larly, we conducted a controlled trial comparing the antiviral effect of a-IFN and 
zidovudine with that of a-IFN and placebo after both in vitro and in vivo pilot studies 
showed that zidovudine caused a decrease in HBV replication (35-37). a-IFN and 
zidovudine were given for 16 weeks in doses increasing to 5 MU and 1000 mg daily, 
respectively. Again we were disappointed as there was no significant difference in the 
response rate between the 2 groups and quantitative analyses of viral markers indicated 
that no additional virus-inhibiting effect was obtained by adding zidovudine to the a-IFN 
therapy. Furthermore, in the combination group bone marrow toxicity was prominent, 
leading to reduction of the dose of both a-IFN and zidovudine in more than 40% of the 
cases. 
The conclusion to be derived from these results is that as yet no combination therapy 
appears more effective than a-IFN alone and that several combinations give rise to an 
increase in dose-limiting toxicity. Therefore in future studies a-IFN should only be co-
administered with agents which combine a potent antiviral effect with a very low toxicity 
profile. 
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Response Prediction of Alpha-Interferon Therapy 
Since only one-third of the chronic hepatitis B patients respond to a-IFN therapy and since 
a-IFN is a costly drug associated with marked side effects, it is important to know what 
the chances of a succes are before the start of a-IFN therapy. The most important 
variables which have been found to influence the response to a-IFN are listed in table 2 
(15,16,18,23,38,39). In almost all studies on factors predictive for response, a high 
aminotransferase level and a low level of viral replication (HBV-DNA) appeared to 
enhance the response rate. Because the spontaneous HBeAg seroconversion rate is much 
higher in this type of patient than in other untreated patients it is presumed that the 
immune system is already in an activated state. For this reason some investigators 
question the usefulness of a-IFN for patients with such a profile. From our experience a-
IFN therapy may be beneficial for this group because the response rate with a-IFN is 
higher than that for controls matched for the level of HBV replication and inflammatory 
activity. 
Table 2. Factors with predictive value for the occurrence of HBeAg seroconversion in 
chronic hepatitis B patients treared with a-interferon. 
Pretreatment 
High aminotransferase level 
Low HBV-DNA level 
HlV antibodies absent 
History of acute symptomatic hepatitis 
Short duration of HBsAg positivity 
Non-oriental race 
Absence of immunosuppressive therapy 
Inflammatory activity on liver biopsy 
During treatment 
Rise or peak of aminotransferases 
HBV-DNA negativity 
Rise of IgM anti-HBc 
Brook and associates applied univariate and logistic regression analysis to pretreatment 
variables of 114 chronic hepatitis B patients treated with a-IFN (40). They found the 
levels of HBV -DNA and aspartate aminotransferase as well as the history of acute 
hepatitis to be independently related to response. Using these same variables plus the HlV 
status they constructed a model which could predict a response to therapy with a sensiti-
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vity and specificty of about 80%. Although the accuracy of this model could be improved, 
it does help physicians to estimate the chances of response and possibly also the best time 
for starting therapy. Furthermore, this model helps investigators to determine whether a 
certain response rate in an uncontrolled population is caused by selection of the patients or 
by modification of the a-IFN therapy. 
So far all studies on response prediction have been applied on patients who had not been 
treated with a-IFN previously. Evaluation of the results of a-IFN retreatment of a group 
of 18 patients who did not respond to an initial 16-week a-IFN course revealed that after 
1 year of follow-up ouly 11% of the patients had responded to the second a-IFN course 
(41). This low response rate did not seem to be related to important clinical characteristics 
that influence the response to initial a-IFN therapy, suggesting that previous nonresponse 
in itself or other (unknown) factors could play an important role in response prediction. A 
large controlled trial which is in progress will further elucidate the benefit of a-IFN 
retreatment. 
Quantitative Monitoring of HBV Replication 
HBV-DNA, HBV-DNA polymerase and HBeAg are the most frequently used parameters 
of HBV replication. Until recently these markers were only assessed qualitatively or 
semiquantitatively. The availability of successful antiviral therapy has led to the need for 
quantitative monitoring of viral replication. Close monitoring of quantified HBV markers 
during an a-IFN course gives the physician important information on the therapeutic effect 
which in turn supports the process of medical-decision making and determines modifica-
tion of the treatment schedule. For example, on the basis of a decline or stabilization of 
the HBV-DNA level one could decide to continue or stop therapy, respectively (23). 
HBV-DNA and HBV-DNA polymerase 
During successful a-IFN therapy the usual sequence of the disappearance of viral markers 
in serum is HBV-DNA polymerase, HBV-DNA and HBeAg. HBV-DNA and HBV-DNA 
polymerase are widely used in research laboratories but not yet in routine diagnostics ( 42-
44). Since HBV-DNA polymerase activity is a marker which can ouly be detected by 
laborious methods that yield results with a rather low sensitivity for loss of viral replica-
tion, it is increasingly being replaced by HBV-DNA (45). HBV-DNA provides a more 
direct indication of the presence of infectious viral particles and has therefore become an 
important parameter of the effect of a-IFN therapy. Dot spot or liquid phase hybridization 
methods can be applied to measure HBV-DNA, yielding a sensitivity of about 10'' to 10' 
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genomes per ml (46,47). In a comparison of two commercially available HBV-DNA 
assays we found a good correlation between the HBV-DNA concentrations (48). However, 
the actual agreement of the results was low because the HBV-DNA level between the 
assays consistently differed by a factor 5 to 10. These discordant results were most 
probably due to differences in standardization of the positive control samples, indicating 
the need for a uniform HBV-DNA reference panel (49). In addition to conventional 
techniques HBV-DNA can also be assessed by means of the polymerase chain reaction 
(PCR) (50-52). By in vitro amplification of target DNA, levels below 10 genomes can be 
detected. The clinical relevance of this extremely sensitive method is as yet unknown 
because many HBsAg-positive carriers with inactive liver disease are still HBV-DNA 
positive by PCR. Longitudinal studies bave demonstrated that a negativate PCR assesse-
ment of HBV-DNA often approximates the moment of HBsAg seroconversion (20). 
Hepatitis B related Alztigens 
Of the HBV antigens present in serum HBeAg probably reflects the level of HBV 
replication most directly. For patients infected with wild type HBV the dynamics of the 
HBeAg level correlate closely with those of the HBV-DNA and HBV-DNA polymerase 
levels (23,53). HBeAg seroconversion is an important event which indicates a transition 
from HBV replication to viral latency. Unlike HBV-DNA negativity determined by dot-
blot or solution hybridization methods, which can be followed by a relapse, HBeAg 
seroconversion is almost always sustained (20,23). Therefore, quantitative HBeAg 
assessment could be used both for monitoring and endpoint determination of antiviral 
therapy in patients carrying wild type HBV (53). At present a standard test for quantitative 
measurement of HBeAg is being developed (L. Mimms, personal communication) (54). 
Patients carrying a mutant type of HBV with a deletion in the pre-core region of the 
genome cannot produce HBeAg and often have active viral replication in the absence 
HBeAg (55,56). Although the efficacy of a-IFN against this HBV variant is still a subject 
of debate (57,58), obviously HBV-DNA and not HBeAg is the viral marker of choice for 
monitoring treatment of these patients. 
Other viral antigens which can be detected in serum are the s gene encoded proteins 
HBsAg, pre-Sl Ag and pre-S2 Ag. All 3 markers bave been found to correlate with the 
degree of HBV replication (59-61). Patients who were followed during a-IFN therapy 
exhibited a good correlation between the HBsAg and the HBeAg or HBV-DNA level (62). 
Since more than 90% of the patients who respond (HBeAg and HBV-DNA negative) to a-
IFN remain HBsAg positive, the HBsAg cannot serve as an assessment for the endpoint of 
a-IFN therapy. Furthermore, the wide range of HBsAg concentrations necessitate the use 
127 
of dilution steps in the quantitative measurement of this antigen. Nevertheless, for those 
laboratories without the possibility to measure HBV-DNA or HBeAg quantitatively, 
HBsAg measurement might be an alternative for assessment of changes in HBV replicati-
on. HBsAg could also be a marker of interest for patients with hepatitis D or pre-core 
mutants who often have active disease without the presence of HBeAg. 
Decompensated Liver Disease and Alpha-Interferon 
As in other forms of liver disease, indicators of hnpaired liver function (bilirubin, 
albumin, coagulation factors) and portal hypertension (ascites and vaticeal bleeding) are 
related to the survival of patients with HBsAg-positive cirrhosis (63-65). In addition to 
these variables the HBeAg status also seetuS to be a factor that influences life expectancy 
of cirrhotic HBV patients since the event of HBeAg seroconversion is associated with 
prolonged survival (65). However, if patients exhibit signs of hepatic decompensation the 
HBeAg status appears to loose its predictive value, suggesting that HBeAg seroconversion 
in decompensated patients - whether a-IFN-induced or not - will not lead to an hnproved 
prognosis. Nevertheless, anecdotal results in the USA indicate that a-IFN-induced arrest 
of HBV replication in decompensated patients may lead to termination of disease progres-
sion, disappearance of symptoms and preservation of the remaining hepatic function (66). 
During therapy the majority of patients developed serious bacterial infections requiriog 
antibiotic therapy. Moreover, either exacerbation of hepatitis or side effects led to 
restriction of dose and/or duration of therapy in all cases. ln addition to its potential 
therapeutic effect on the patient's own liver a-IFN may also be beneficial for patients with 
decompensated disease for which liver transplantation remains the only realistic therapeu-
tic option. In these patients pretransplant transition to viral latency would reduce the risk 
of infection of the graft (67). Currently a controlled trial to investigate the benefit of low 
dose a-IFN for patients with decompensated HBV cirrhosis is in progress (R. Perrillo, 
personal communication). 
That a-IFN therapy for patients with (decompensated) cirrhosis is not without risks was 
illnstrated by 9 reported cases of fatal decompensation during or shortly after a-IFN 
therapy (68,69). Ail patients had cirrhosis and 5 did not have signs of decompensation at 
the start of therapy. It is conceivable that the transient exacerbation of hepatitis, which is a 
sign of a-IFN-facilitated hepatocyte lysis, could be deadly in patients with limited residnal 
liver capacity. One of the 9 patients first received a short -term prednisone course which 
could have been an additional factor in the occunence of fatal decompensation (70). One 
could conclude from these results that physicians should closely monitor a-IFN-treated 
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patients with cirrhosis; when signs of decompensation occur therapy should be discontinu-
ed immediately. Patients with decompensated cirrhosis should only be treated with a-IFN 
on strict indications and under careful monitoting, preferably in a centre with a liver 
transplantation programme. It seems prudent to start with low dose a-IFN therapy (1-2 
MU thrice weekly) and carefully adapt the dose according to the clinical, biochemical and 
vitological parameters. 
Adverse Effects of Alpha-Interferon 
The variety of side effects associated with a-IFN therapy is well known. Table 3 lists the 
most frequently reported side effects in 100 consecutive chronic hepatitis B patients treated 
with a-IFN (71). Fever, myalgia and other flu-like symptoms are seen in the majority of 
the patients duting the initial days of therapy but can be suppressed by paracetamol or 
indomethacin therapy. Administration of these drugs does not affect the antiviral or 
immunomodulating effects of a-IFN (72); indomethacin might even enhance the action of 
a-IFN (73). After the first week of therapy complaints of fatigue, apathy and anorexia 
prevail. Fortunately, most adverse effects are reversible with dose reduction or disconti-
nuation of therapy. 
Table 3. Side effects during a-interferon therapy in 100 consecutive HBV patients. 
Fatigue 
Fever/Malaise 
Myalgia 
Leukopenia ( < 3 x 1 0911) 
Anorexia 
Gastrointestinal problems 
Depression/lethargy 
Loss of hair 
Weight loss (>5%) 
Trombocytopenia (<50 x 109/1) 
Neurotoxicity 
Incidence 
74% 
61% 
58% 
56% 
29% 
28% 
24% 
21% 
18% 
7% 
7% 
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Cause ofiFN 
dose reduction 
11% 
4% 
8% 
3% 
4% 
4% 
A serious side effect of a-IFN which is mostly not reversible is autoimmune-mediated 
thyroid disease (74). Although it appears to be confined mainly to hepatitis C, both 
hyperthyroidism and hypothyroidism can also occur during a-IFN therapy for HBV-iofec-
ted patients. Sioce these diseases can be treated successfully, screemng of thyroid 
hormones before and during therapy is recommended. 
Neuropsychiatric Side Effects 
A group of underestimated symptoms ioduced by a-IFN is the spectrum attributable to 
neuropsychiatric toxicity. In particular lethargy, loss of concentration, depressive feeliogs, 
emotional lability and irritability are not always diagnosed or thought to be related to a-
IFN therapy (75,76). These symptoms appear rather innocent but they often give rise to 
domestic problems or temporary discontinuation of work. The best way to reduce these 
problems is careful explanation that the symptoms are treatment-related and will disappear 
once therapy has been discontinued. As a second step dose reduction or psychiatric 
counseliog should be considered. More serious forms of neuropsychiatric toxicity ioclude 
depression, psychosis and seizures (77, 78). One of the most dramatic consequences of the 
serious psychiatric disorders arisiog from a-IFN therapy is suicidal behavior. Reuault et 
a!. described one patient who became suicidal during a-IFN therapy (77). After an exten-
sive survey io 16 European hospitals we found 5 cases of attempted and 3 of completed 
suicide among a total of about 2,500 chronic viral hepatitis patients on a-IFN therapy 
(79). Even though it appears to be an uncommon event and we cannot prove directly that 
the suicides were caused by a-IFN, the fact that none of the patients had a psychiatric 
history, none had a poor life expectancy and all developed serious psychiatric disorders 
(depression, psychosis and delirium) during a-IFN therapy argne io favor of a relation 
between a-IFN therapy and suicide. Therefore, although this complication is rare it is so 
dangerous that it is important to iostruct patients and family to recognize signs suggestive 
of serious cognitive dysftmction and affective disturbances. If these signs occur psychiatric 
consultation and/ or discontinuation of therapy is warranted. 
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SUMMARY 
The positive results of a-interferon (IFN) therapy have generated an important change in 
the therapeutic approach of chronic hepatitis B patients. The studies presented in this 
thesis are directed to the question how the efficacy of a-IFN therapy for chronic hepatitis 
B could be improved (chapter 1). In particular we investigated whether patient selection, 
modification of the treatment schedule and new virological assessments could contribute to 
answer this question. 
For optimal management of the HBV-infected patients it is important to defme indications 
for new treatment modalities as a-IFN and liver transplantation. We followed a cohort of 
98 patients with HBsAg-positive cirrhosis and determined which variables influenced the 
survival (chapter 2). High age, the presence of ascites and a high serum bilirubin level 
were indepently associated with a short duration survival. For the group with a 
compensated cirrhosis HBeAg-negative patients exhibited a significantly better prognosis 
than HBeAg-positive patients. In contrast we could not fmd a difference in survival in 
decompensated patients with a different HBeAg status. These fmdings suggest that there is 
an indication for antiviral therapy for patients with a compensated hepatitis B cirrhosis and 
active viral replication (HBeAg positive) whereas liver transplantation appears the major 
therapeutic option for patients with a decompensated chronic hepatitis B infection. 
The standard course of a-IFN therapy for chronic hepatitis B lasts 16 weeks and leads in 
about one third of the patients to cessation of virus replication. Intermittent a-IFN therapy 
of 24 weeks duration and prolongation of treatment in patients who already exhibited a 
partial response (HBV-DNA negative) could enhance the HBeAg serocvonversion rate 
(chapter 3). Another modification of the standard a-IFN treatment is combination therapy 
with zidovudine. In a randomized controlled study (chapter 4) we found that this 
combination was not more effective than a-IFN monotherapy. In patients treated with the 
combination of a-IFN and zidovudine side effects, in particular anemia and leucopenia, 
were more prominent than in those treated with a-IFN and placebo. In chapter 5 the 
benefit of a-IFN retreatment in chronic hepatitis B patients who previously failed to 
respond was evaluated. A response (HBeAg seroconversion) to therapy occurred in 2 of 
the 18 (11 %) investigated patients. This response rate may be comparable to the 
spontaneous HBeAg seroconversion incidence and therefore the efficacy of a-IFN 
retreatment in chronic hepatitis B appears limited. Variables with a known predictive 
value towards response for initial a-IFN courses (e.g. the level of inflammatory acitvity) 
did not influence the result of the retreatment. 
An important aspect of antiviral therapy in chronic hepatitis B is monitoring of quantitated 
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viral markers. Using these markers one could inform patients during a-IFN treatment 
about the effect of the therapy and one could either prolong or stop therapy in case of a 
partial or no response, respectively. The most important marker reflecting the level of 
virus replication is the Hepatitis B virus DNA (HBV-DNA). We compared 2 HBV-DNA 
test systems (Abbott HBV-DNA assay, Abbott and Aff!Probe assay, Orion) in sera 
obtained from patients treated with a-IFN (chapter 6). Although there was a good 
correlation between the HBV-DNA results of the assays the AffiProbe test yielded 
systematically 5 to 10 times higher HBV-DNA values than the Abbott assay. These 
discordant results were most probably due to differences in the standardization of the 
positive control samples of the test systems indicating the need for a uniform HBV-DNA 
reference panel. Since HBV-DNA can ouly be measured quantitatively with time-
consuming and costly methods its detection has been resrricted to research laboratories so 
far. For the many hospitals not having the possibility to assess HBV-DNA there ntigbt be 
a cheap and simpel alternative, quantitative HBsAg measurement. The level of HBsAg 
decreases significantly after cessation of HBV replication (HBeAg seroconversion) and for 
patients who were followed during a-IFN therapy we found a good correlation between 
the HBsAg level and both the quantitative HBV-DNA and HBeAg values, irrespective of 
the result of therapy (chapter 7). 
Due to a virus specific immunological response a-IFN can cause a transient exacerbation 
of inflammatory activity in chronic hepatitis B patients. This exacerbation could lead to a 
fatal hepatic decompensation in patients with cirrhosis (chapter 8). After a patient in our 
institute died due to a fatal decompensation during a-IFN therapy we sent out a 
questionnaire to study the frequency and clinical aspects of this serious complication. 
Among 2490 patients 8 additional cases with fatal hepatic decompensation during a-IFN 
therapy were reported. Seizures and suicide attempts are 2 other complications associated 
with a-IFN therapy of patients with chronic viral hepatitis. In chapters 9 and 10 we 
described several patients who exhibited these serious neuropsychiarric adverse events of 
a-JFN treatment. 
In the chapter 11 the findings of studies presented in this thesis are discussed within an 
overview of other recent developments of a-IFN therapy for chronic hepatitis B. 
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SAMENV ATTING 
De hoopgevende hehandelingsresultaten met O<-interferon (lFN) hebben in de laatste jaren 
geleid tot een belangrijke wijziging in het medisch handelen bij patienten met chronische 
hepatitis B. Het onderzoek in deze dissertatie richt zich op de vraag hoe de effectiviteit 
van O<-IFN behandeling bij chronische hepatitis B verbeterd kan worden (hoofdstuk 1). 
Met name is onderzocht in welke mate de selectie van patienten. verandering van het 
hehandelingsschema en nieuwe virologische vervolgmethoden hieraan kunnen bijdragen. 
Het is voor een goed medisch beleid belangrijk om te weten in welke fase van de 
leverziekte hehandeling met O<-IFN geindiceerd is en wanneer beter overgegaan kan 
worden op levertransplantatie. Wij onderzochten welke factoren de overleving van een 
cohort van 98 patienten met een HBV-gerelateerde levercirrhose beinvloeden. Hoge 
leeftijd, de aanwezigheid van ascites en een hoog serum bilirubine-gehalte waren 
onafhankelijk van andere factoren geassocieerd met een korte overlevingsduur. In de 
groep met een gecompenseerde cirrhose hadden HBeAg-negatieve patienten een significant 
langere overleving dan HBeAg-positieve patienten. In tegenstelling was er bij de groep 
van gedecompenseerde patienten geen verschil in overleving bij patienten met een 
verschillende HBeAg status. Deze bevinding suggereert dat er voor patienten met een 
gecompenseerde hepatitis B cirrhose met virus replicatie (HBeAg positief) een indicatie 
bestaat om door middel van antivirale behandeling een viruslatentie te induceren terwijl bij 
patienten met een gedecompenseerde leverziekte levertransplantatie waarschijnlijk de 
belangrijkste therapeutische optie is. 
De standaard O<-IFN behandeling bij chronische hepatitis B duurt 16 weken en leidt in 
ongeveer een derde van de patienten tot een verdwijning van de virusreplicatie. 
Intermitterende hehandeling gedurende 24 weken en een verlenging van de behandeling bij 
patienten die a! een partiele response (HBV-DNA negatief) vertonen zou mogelijk kunnen 
lei den tot een verhoging van bet aantal HBeAg seroconversies (hoofdstuk 3). Een andere 
modificatie van de standaard behandeling met O<-IFN is combinatie therapie met 
zidovudine. In een gecontroleerd onderzoek (hoofdstuk 4) werd aangetoond dat deze 
combinatie niet effectiever is dan O<-IFN monotherapie. In de groep behandeld met de 
combinatie van O<-IFN en zidovudine waren er beduidend meer bijwerkingen, met name 
anemie en leukopenie, dan in de groep die aileen O<-IFN kteeg. In hoofdstuk 5 wordt 
nagegaan of herhehandeling van chronische hepatitis B patienten die bij een voorgaande 
behandeling geen response (HBeAg seroconversie) ondergingen effectief is. Van de 18 
patienten waren er slechts 2 (ll %) die een response vertoonden. Dit percentage is niet 
boger dan het spontane HBeAg seroconversie percentage en de effectiviteit van 
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herbehandeling met a-IFN lijkt dus beperkt. Factoren die een bewezen predictieve waarde 
ten aanzien van de response bij een eerste a-IFN therapie hebben (bijvoorbeeld het niveau 
van ontstekingsactiviteit) bleken de nitkomst van de herbehandeling Diet te beinvloeden. 
Een belangrijk aspect van de antivirale behandeling bij chronische hepatitis B is het 
vervolgen van gekwantificeerde virusparameters (hoofdstuk 6 en 7). Bij a-IFN therapie 
kan men met behulp van deze waarden de patient informeren over het beloop van de 
behandeling en kan men bepalen of er a! dan niet een response aanstaande is zodat de 
behandeling respectievelijk gecontinueerd of gestopt dient te worden. Een van de 
belangrijkste parameters die de mate van virusreplicatie weergeven is het hepatitis B virus 
DNA (HBV-DNA). Wij hebben 2 HBV-DNA testsystemen (HBV-DNA assay, Abbott en 
AffiProbe assay, Orion) vergeleken in sera van patienten behandeld met a-IFN. Hoewel er 
een zeer goede correlatie bleek te bestaan tussen de HBV-DNA nitslagen van de 2 testen 
was er een systematisch 5 tot 10-voudig verschil mssen de uitkomsten. Uit onderzoek naar 
positieve controle panels van de testen bleek er een verschil in de standaardisatie van de 
hoeveelheid HBV-DNA in deze panels te zijn. Deze bevinding maakt duidelijk dat er 
behoefte is aan een uniform HBV-DNA referentiepanel. Omdat het HBV-DNA aileen met 
behulp van bewerkelijke en kostbare methoden kwantitatief gemeten kan worden is de 
nitvoering van deze bepaling vooralsnog beperkt tot gespecialiseerde laboratoria. Voor de 
vele centra die Diet de mogelijkheid hebben om HBV -DNA te meten is er wellicht een 
goedkoop en simpel alternatief, de kwantitatieve HBsAg bepaling. De HBsAg concentratie 
in serum blijkt significant te dalen na het verdwijnen van de virusreplicatie (HBeAg 
seroconversie) en bij patienten die vervolgd zijn tijdens behandeling met a-IFN blijkt er 
onafhankelijk van de uitkomst van de therapie een goede correlatie te zijn mssen het de 
kwantitatieve HBsAg waarden en zowel de kwantitatieve HBV-DNA als HBeAg waarden. 
Bij a-IFN behandeling van chronische hepatitis B patienten kan er een door het 
immuunsysteem gegenereerde tijdelijke exacerbatie van ontstekingsactiviteit optreden. 
Deze exacerbatie kan bij patienten met een cirrhose leiden tot een fatale 
leverdecompensatie (hoofdstuk 8). Naar aanleiding van een dergelijke casus in ons 
ziekenhnis onderzochten wij met behulp van een enquete de frequentie en klinische 
aspecten van deze ernstige complicatie van de behandeling. Epilepsie en suicidepogingen 
zijn 2 andere ernstige complicaties welke gerelateerd lijken te zijn aan a-IFN therapie bij 
chronische virale hepatitis. In hoofdstuk 9 en 10 zijn enkele cases beschreven die de 
kliniek van deze ernstige neuropsychiatrische bijwerkingen weergeven. 
In de discussie (hoofdstuk 11) worden de bevindingen van de studies nit dit proefschrift 
geplaatst binnen een overzicht van andere recente ontwikkelingen van antivirale 
behandeling met a-IFN bij chronische hepatitis B. 
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